<?xml version="1.0"?>
<presentation title="Endocrine treatment of breast cancer flash v7" width="720.0000000" height="540.0000000" thmbWidth="78.0000000" thmbHeight="59.0000000" frameRate="24.0000000" looping="0" startingSlideShow="" pptVersion="2016" type="compound" hasExternalAudio="0" uid="{72C0429F-FC8A-44E7-B152-D6826999A52C}">
	<presenters/>
	<references/>
	<soundAssets/>
	<sharedAssetsLibrary src="assets.swf"/>
	<graphicAssets>
		<graphicAsset id="imgAsset0" src="thmb1.swf" embedded="0"/>
		<graphicAsset id="imgAsset1" src="thmb2.swf" embedded="0"/>
		<graphicAsset id="imgAsset2" src="thmb3.swf" embedded="0"/>
		<graphicAsset id="imgAsset3" src="thmb4.swf" embedded="0"/>
		<graphicAsset id="imgAsset4" src="thmb5.swf" embedded="0"/>
		<graphicAsset id="imgAsset5" src="thmb6.swf" embedded="0"/>
		<graphicAsset id="imgAsset6" src="thmb7.swf" embedded="0"/>
		<graphicAsset id="imgAsset7" src="thmb8.swf" embedded="0"/>
		<graphicAsset id="imgAsset8" src="thmb9.swf" embedded="0"/>
		<graphicAsset id="imgAsset9" src="thmb10.swf" embedded="0"/>
		<graphicAsset id="imgAsset10" src="thmb11.swf" embedded="0"/>
		<graphicAsset id="imgAsset11" src="thmb12.swf" embedded="0"/>
		<graphicAsset id="imgAsset12" src="thmb13.swf" embedded="0"/>
		<graphicAsset id="imgAsset13" src="thmb14.swf" embedded="0"/>
		<graphicAsset id="imgAsset14" src="thmb15.swf" embedded="0"/>
		<graphicAsset id="imgAsset15" src="thmb16.swf" embedded="0"/>
		<graphicAsset id="imgAsset16" src="thmb17.swf" embedded="0"/>
		<graphicAsset id="imgAsset17" src="thmb18.swf" embedded="0"/>
		<graphicAsset id="imgAsset18" src="thmb19.swf" embedded="0"/>
		<graphicAsset id="imgAsset19" src="thmb20.swf" embedded="0"/>
		<graphicAsset id="imgAsset20" src="thmb21.swf" embedded="0"/>
		<graphicAsset id="imgAsset21" src="thmb22.swf" embedded="0"/>
		<graphicAsset id="imgAsset22" src="thmb23.swf" embedded="0"/>
		<graphicAsset id="imgAsset23" src="thmb24.swf" embedded="0"/>
		<graphicAsset id="imgAsset24" src="thmb25.swf" embedded="0"/>
		<graphicAsset id="imgAsset25" src="thmb26.swf" embedded="0"/>
		<graphicAsset id="imgAsset26" src="thmb27.swf" embedded="0"/>
		<graphicAsset id="imgAsset27" src="thmb28.swf" embedded="0"/>
		<graphicAsset id="imgAsset28" src="thmb29.swf" embedded="0"/>
		<graphicAsset id="imgAsset29" src="thmb30.swf" embedded="0"/>
		<graphicAsset id="imgAsset30" src="thmb31.swf" embedded="0"/>
		<graphicAsset id="imgAsset31" src="thmb32.swf" embedded="0"/>
		<graphicAsset id="imgAsset32" src="thmb33.swf" embedded="0"/>
		<graphicAsset id="imgAsset33" src="thmb34.swf" embedded="0"/>
		<graphicAsset id="imgAsset34" src="thmb35.swf" embedded="0"/>
		<graphicAsset id="imgAsset35" src="thmb36.swf" embedded="0"/>
		<graphicAsset id="imgAsset36" src="thmb37.swf" embedded="0"/>
		<graphicAsset id="imgAsset37" src="thmb38.swf" embedded="0"/>
		<graphicAsset id="imgAsset38" src="thmb39.swf" embedded="0"/>
		<graphicAsset id="imgAsset39" src="thmb40.swf" embedded="0"/>
		<graphicAsset id="imgAsset40" src="thmb41.swf" embedded="0"/>
		<graphicAsset id="imgAsset41" src="thmb42.swf" embedded="0"/>
		<graphicAsset id="imgAsset42" src="thmb43.swf" embedded="0"/>
		<graphicAsset id="imgAsset43" src="thmb44.swf" embedded="0"/>
		<graphicAsset id="imgAsset44" src="thmb45.swf" embedded="0"/>
		<graphicAsset id="imgAsset45" src="thmb46.swf" embedded="0"/>
		<graphicAsset id="imgAsset46" src="thmb47.swf" embedded="0"/>
		<graphicAsset id="imgAsset47" src="thmb48.swf" embedded="0"/>
		<graphicAsset id="imgAsset48" src="thmb49.swf" embedded="0"/>
		<graphicAsset id="imgAsset49" src="thmb50.swf" embedded="0"/>
		<graphicAsset id="imgAsset50" src="thmb51.swf" embedded="0"/>
		<graphicAsset id="imgAsset51" src="thmb52.swf" embedded="0"/>
		<graphicAsset id="imgAsset52" src="thmb53.swf" embedded="0"/>
		<graphicAsset id="imgAsset53" src="thmb54.swf" embedded="0"/>
		<graphicAsset id="imgAsset54" src="thmb55.swf" embedded="0"/>
		<graphicAsset id="imgAsset55" src="thmb56.swf" embedded="0"/>
		<graphicAsset id="imgAsset56" src="thmb57.swf" embedded="0"/>
		<graphicAsset id="imgAsset57" src="thmb58.swf" embedded="0"/>
		<graphicAsset id="imgAsset58" src="thmb59.swf" embedded="0"/>
		<graphicAsset id="imgAsset59" src="thmb60.swf" embedded="0"/>
		<graphicAsset id="imgAsset60" src="thmb61.swf" embedded="0"/>
		<graphicAsset id="imgAsset61" src="thmb62.swf" embedded="0"/>
		<graphicAsset id="imgAsset62" src="thmb63.swf" embedded="0"/>
		<graphicAsset id="imgAsset63" src="thmb64.swf" embedded="0"/>
		<graphicAsset id="imgAsset64" src="thmb65.swf" embedded="0"/>
		<graphicAsset id="imgAsset65" src="thmb66.swf" embedded="0"/>
		<graphicAsset id="imgAsset66" src="thmb67.swf" embedded="0"/>
		<graphicAsset id="imgAsset67" src="thmb68.swf" embedded="0"/>
		<graphicAsset id="imgAsset68" src="thmb69.swf" embedded="0"/>
		<graphicAsset id="imgAsset69" src="thmb70.swf" embedded="0"/>
		<graphicAsset id="imgAsset70" src="thmb71.swf" embedded="0"/>
		<graphicAsset id="imgAsset71" src="thmb72.swf" embedded="0"/>
		<graphicAsset id="imgAsset72" src="thmb73.swf" embedded="0"/>
		<graphicAsset id="imgAsset73" src="thmb74.swf" embedded="0"/>
		<graphicAsset id="imgAsset74" src="thmb75.swf" embedded="0"/>
		<graphicAsset id="imgAsset75" src="thmb76.swf" embedded="0"/>
		<graphicAsset id="imgAsset76" src="thmb77.swf" embedded="0"/>
		<graphicAsset id="imgAsset77" src="thmb78.swf" embedded="0"/>
		<graphicAsset id="imgAsset78" src="thmb79.swf" embedded="0"/>
		<graphicAsset id="imgAsset79" src="thmb80.swf" embedded="0"/>
		<graphicAsset id="imgAsset80" src="thmb81.swf" embedded="0"/>
		<graphicAsset id="imgAsset81" src="thmb82.swf" embedded="0"/>
		<graphicAsset id="imgAsset82" src="thmb83.swf" embedded="0"/>
		<graphicAsset id="imgAsset83" src="thmb84.swf" embedded="0"/>
		<graphicAsset id="imgAsset84" src="thmb85.swf" embedded="0"/>
		<graphicAsset id="imgAsset85" src="thmb86.swf" embedded="0"/>
		<graphicAsset id="imgAsset86" src="thmb87.swf" embedded="0"/>
		<graphicAsset id="imgAsset87" src="thmb88.swf" embedded="0"/>
		<graphicAsset id="imgAsset88" src="thmb89.swf" embedded="0"/>
		<graphicAsset id="imgAsset89" src="thmb90.swf" embedded="0"/>
		<graphicAsset id="imgAsset90" src="thmb91.swf" embedded="0"/>
		<graphicAsset id="imgAsset91" src="thmb92.swf" embedded="0"/>
		<graphicAsset id="imgAsset92" src="thmb93.swf" embedded="0"/>
		<graphicAsset id="imgAsset93" src="thmb94.swf" embedded="0"/>
		<graphicAsset id="imgAsset94" src="thmb95.swf" embedded="0"/>
		<graphicAsset id="imgAsset95" src="thmb96.swf" embedded="0"/>
		<graphicAsset id="imgAsset96" src="thmb97.swf" embedded="0"/>
		<graphicAsset id="imgAsset97" src="thmb98.swf" embedded="0"/>
		<graphicAsset id="imgAsset98" src="thmb99.swf" embedded="0"/>
		<graphicAsset id="imgAsset99" src="thmb100.swf" embedded="0"/>
		<graphicAsset id="imgAsset100" src="thmb101.swf" embedded="0"/>
		<graphicAsset id="imgAsset101" src="thmb102.swf" embedded="0"/>
		<graphicAsset id="imgAsset102" src="thmb103.swf" embedded="0"/>
		<graphicAsset id="imgAsset103" src="thmb104.swf" embedded="0"/>
		<graphicAsset id="imgAsset104" src="thmb105.swf" embedded="0"/>
		<graphicAsset id="imgAsset105" src="thmb106.swf" embedded="0"/>
		<graphicAsset id="imgAsset106" src="thmb107.swf" embedded="0"/>
		<graphicAsset id="imgAsset107" src="thmb108.swf" embedded="0"/>
		<graphicAsset id="imgAsset108" src="thmb109.swf" embedded="0"/>
		<graphicAsset id="imgAsset109" src="thmb110.swf" embedded="0"/>
		<graphicAsset id="imgAsset110" src="thmb111.swf" embedded="0"/>
		<graphicAsset id="imgAsset111" src="thmb112.swf" embedded="0"/>
		<graphicAsset id="imgAsset112" src="thmb113.swf" embedded="0"/>
		<graphicAsset id="imgAsset113" src="thmb114.swf" embedded="0"/>
		<graphicAsset id="imgAsset114" src="thmb115.swf" embedded="0"/>
		<graphicAsset id="imgAsset115" src="thmb116.swf" embedded="0"/>
		<graphicAsset id="imgAsset116" src="thmb117.swf" embedded="0"/>
		<graphicAsset id="imgAsset117" src="thmb118.swf" embedded="0"/>
		<graphicAsset id="imgAsset118" src="thmb119.swf" embedded="0"/>
		<graphicAsset id="imgAsset119" src="thmb120.swf" embedded="0"/>
		<graphicAsset id="imgAsset120" src="thmb121.swf" embedded="0"/>
		<graphicAsset id="imgAsset121" src="thmb122.swf" embedded="0"/>
		<graphicAsset id="imgAsset122" src="thmb123.swf" embedded="0"/>
		<graphicAsset id="imgAsset123" src="thmb124.swf" embedded="0"/>
		<graphicAsset id="imgAsset124" src="thmb125.swf" embedded="0"/>
		<graphicAsset id="imgAsset125" src="thmb126.swf" embedded="0"/>
		<graphicAsset id="imgAsset126" src="thmb127.swf" embedded="0"/>
		<graphicAsset id="imgAsset127" src="thmb128.swf" embedded="0"/>
		<graphicAsset id="imgAsset128" src="thmb129.swf" embedded="0"/>
		<graphicAsset id="imgAsset129" src="thmb130.swf" embedded="0"/>
		<graphicAsset id="imgAsset130" src="thmb131.swf" embedded="0"/>
		<graphicAsset id="imgAsset131" src="thmb132.swf" embedded="0"/>
		<graphicAsset id="imgAsset132" src="thmb133.swf" embedded="0"/>
		<graphicAsset id="imgAsset133" src="thmb134.swf" embedded="0"/>
		<graphicAsset id="imgAsset134" src="thmb135.swf" embedded="0"/>
		<graphicAsset id="imgAsset135" src="thmb136.swf" embedded="0"/>
		<graphicAsset id="imgAsset136" src="thmb137.swf" embedded="0"/>
		<graphicAsset id="imgAsset137" src="thmb138.swf" embedded="0"/>
		<graphicAsset id="imgAsset138" src="thmb139.swf" embedded="0"/>
		<graphicAsset id="imgAsset139" src="thmb140.swf" embedded="0"/>
		<graphicAsset id="imgAsset140" src="thmb141.swf" embedded="0"/>
		<graphicAsset id="imgAsset141" src="thmb142.swf" embedded="0"/>
		<graphicAsset id="imgAsset142" src="thmb143.swf" embedded="0"/>
		<graphicAsset id="imgAsset143" src="thmb144.swf" embedded="0"/>
		<graphicAsset id="imgAsset144" src="thmb145.swf" embedded="0"/>
		<graphicAsset id="imgAsset145" src="thmb146.swf" embedded="0"/>
		<graphicAsset id="imgAsset146" src="thmb147.swf" embedded="0"/>
		<graphicAsset id="imgAsset147" src="thmb148.swf" embedded="0"/>
		<graphicAsset id="imgAsset148" src="thmb149.swf" embedded="0"/>
		<graphicAsset id="imgAsset149" src="thmb150.swf" embedded="0"/>
		<graphicAsset id="imgAsset150" src="thmb151.swf" embedded="0"/>
		<graphicAsset id="imgAsset151" src="thmb152.swf" embedded="0"/>
		<graphicAsset id="imgAsset152" src="thmb153.swf" embedded="0"/>
		<graphicAsset id="imgAsset153" src="thmb154.swf" embedded="0"/>
		<graphicAsset id="imgAsset154" src="thmb155.swf" embedded="0"/>
		<graphicAsset id="imgAsset155" src="thmb156.swf" embedded="0"/>
		<graphicAsset id="imgAsset156" src="thmb157.swf" embedded="0"/>
		<graphicAsset id="imgAsset157" src="thmb158.swf" embedded="0"/>
		<graphicAsset id="imgAsset158" src="thmb159.swf" embedded="0"/>
		<graphicAsset id="imgAsset159" src="thmb160.swf" embedded="0"/>
		<graphicAsset id="imgAsset160" src="thmb161.swf" embedded="0"/>
		<graphicAsset id="imgAsset161" src="thmb162.swf" embedded="0"/>
		<graphicAsset id="imgAsset162" src="thmb163.swf" embedded="0"/>
		<graphicAsset id="imgAsset163" src="thmb164.swf" embedded="0"/>
		<graphicAsset id="imgAsset164" src="thmb165.swf" embedded="0"/>
		<graphicAsset id="imgAsset165" src="thmb166.swf" embedded="0"/>
		<graphicAsset id="imgAsset166" src="thmb167.swf" embedded="0"/>
		<graphicAsset id="imgAsset167" src="thmb168.swf" embedded="0"/>
		<graphicAsset id="imgAsset168" src="thmb169.swf" embedded="0"/>
		<graphicAsset id="imgAsset169" src="thmb170.swf" embedded="0"/>
		<graphicAsset id="imgAsset170" src="thmb171.swf" embedded="0"/>
		<graphicAsset id="imgAsset171" src="thmb172.swf" embedded="0"/>
		<graphicAsset id="imgAsset172" src="thmb173.swf" embedded="0"/>
		<graphicAsset id="imgAsset173" src="thmb174.swf" embedded="0"/>
		<graphicAsset id="imgAsset174" src="thmb175.swf" embedded="0"/>
	</graphicAssets>
	<playlists/>
	<narration/>
	<settings>
		<navigation>
			<keyboard enabled="1">
				<actions>
					<action name="playPause">
						<shortcut code="32" control="0" shift="0"/>
					</action>
					<action name="nextSlide">
						<shortcut code="34" control="0" shift="0"/>
					</action>
					<action name="previousSlide">
						<shortcut code="33" control="0" shift="0"/>
					</action>
					<action name="nextStep">
						<shortcut code="13" control="0" shift="0"/>
					</action>
					<action name="previousStep">
						<shortcut code="13" control="0" shift="1"/>
					</action>
					<action name="firstSlide">
						<shortcut code="36" control="1" shift="0"/>
					</action>
					<action name="lastSlide">
						<shortcut code="35" control="1" shift="0"/>
					</action>
					<action name="lastViewedSlide">
						<shortcut code="8" control="0" shift="0"/>
					</action>
					<action name="slideStart">
						<shortcut code="36" control="0" shift="0"/>
					</action>
					<action name="slideEnd">
						<shortcut code="35" control="0" shift="0"/>
					</action>
					<action name="seekForward">
						<shortcut code="39" control="0" shift="0"/>
					</action>
					<action name="seekBackward">
						<shortcut code="37" control="0" shift="0"/>
					</action>
					<action name="volumeUp">
						<shortcut code="38" control="0" shift="0"/>
					</action>
					<action name="volumeDown">
						<shortcut code="40" control="0" shift="0"/>
					</action>
					<action name="toggleFullscreen">
						<shortcut code="70" control="1" shift="0"/>
					</action>
				</actions>
			</keyboard>
			<mouse enabled="1" target="step"/>
			<gesture zoom="1"/>
		</navigation>
		<skin>
			<currentTemplate baseId="PRESENTATION"/>
			<colorSettings>
				<color id="button.content.normal">#FFFFFF</color>
				<color id="button.content.over">#FFFFFF</color>
				<color id="button.face.normal">#777777</color>
				<color id="button.face.over">#575757</color>
				<color id="companyLogo.background">#FFFFFF</color>
				<color id="hyperlink">#097CE7</color>
				<color id="listItem.face.over">#E8E8E8</color>
				<color id="listItem.face.pressed">#6E6E6E</color>
				<color id="listItem.label.over">#000000</color>
				<color id="listItem.label.pressed">#FFFFFF</color>
				<color id="listItem.label.visited">#A1A1A1</color>
				<color id="page.background">#8A8A8A</color>
				<color id="panel.background">#F7F7F7</color>
				<color id="panel.text">#323232</color>
				<color id="player.background">#D4D4D4</color>
				<color id="popup.background">#FFFFFF</color>
				<color id="progress.background">#6E6E6E</color>
				<color id="progress.loading">#D0D0D0</color>
				<color id="progress.playback">#A1A1A1</color>
				<color id="text">#4D4D4D</color>
			</colorSettings>
			<controlPanelSettings>
				<visible>true</visible>
				<showOutline>false</showOutline>
				<showPlayPause>true</showPlayPause>
				<showRewind>true</showRewind>
				<showVolumeControl>false</showVolumeControl>
				<showCCButton>false</showCCButton>
				<showPrevButton>true</showPrevButton>
				<showNextButton>true</showNextButton>
				<showSlideOnlyButton>true</showSlideOnlyButton>
				<progressBar>
					<visible>true</visible>
					<enabled>true</enabled>
					<showLabels>true</showLabels>
					<mode>slideTimeline</mode>
				</progressBar>
				<navigationMode>bySlides</navigationMode>
			</controlPanelSettings>
			<titlePanelSettings>
				<showLogo>false</showLogo>
				<visible>false</visible>
				<buttons>
					<button type="attachments" visible="false"/>
					<button type="presenterInfo" visible="false"/>
					<button type="markerTools" visible="false"/>
					<button type="notes" visible="false"/>
					<button type="outline" visible="false"/>
				</buttons>
			</titlePanelSettings>
			<outlinePanelSettings>
				<numberEntries>true</numberEntries>
				<highlightViewedEntries>false</highlightViewedEntries>
				<thumbnails>true</thumbnails>
				<search>true</search>
				<multilevel>false</multilevel>
			</outlinePanelSettings>
			<sidePanelSettings>
				<showAtLeft>false</showAtLeft>
				<showLogo>false</showLogo>
				<showPresenterInfo>false</showPresenterInfo>
				<showPresenterVideo>false</showPresenterVideo>
				<visible>true</visible>
				<tabsPanel>
					<showOutline>true</showOutline>
					<showNotes>false</showNotes>
				</tabsPanel>
			</sidePanelSettings>
		</skin>
		<appearance fullScreen="1" showSlidePreloader="1"/>
		<playback autoStart="1" syncWithVideoNarration="1" enableVideoControl="1" resumePresentationPlayback="never"/>
	</settings>
	<slides embedded="0">
		<slide index="0" title="Endocrine Treatment &amp; Endocrine Resistance in Breast Cancer" titleNormalized="endocrine treatment &amp; endocrine resistance in breast cancer" src="slide1.swf" size="24021" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>1</notes>
			<notesNormalized>1</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;1&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Endocrine Treatment &amp; Endocrine Resistance in Breast Cancer
Endocrine Physiology and Pharmacology
11th of November 2016
Dr Alexey Larionov</text>
		</slide>
		<slide index="1" title="" titleNormalized="" src="slide2.swf" size="6039" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset1">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>2</notes>
			<notesNormalized>2</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;2&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Discussing reading list
Endocrine treatment in breast cancer
Breast Cancer
Oestrogen Receptor

Endocrine treatment

Short group task
Endocrine resistance in breast cancer
Impact &amp; current management
Mechanisms of endocrine resistance
Future: biomarker-guided targeted treatment and monitoring
Plan of the seminar</text>
		</slide>
		<slide index="2" title="" titleNormalized="" src="slide3.swf" size="5197" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset2">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>3</notes>
			<notesNormalized>3</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;3&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Reading list discussion</text>
		</slide>
		<slide index="3" title="" titleNormalized="" src="slide4.swf" size="5301" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset3">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>4</notes>
			<notesNormalized>4</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;4&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Why I recommended these papers ?
Reading list discussion</text>
		</slide>
		<slide index="4" title="" titleNormalized="" src="slide5.swf" size="5315" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset4">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>5</notes>
			<notesNormalized>5</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;5&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>What was the most interesting paper ?
Reading list discussion</text>
		</slide>
		<slide index="5" title="" titleNormalized="" src="slide6.swf" size="34211" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset5">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>6</notes>
			<notesNormalized>6</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;6&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>What was the most interesting paper ?
Reading list discussion</text>
		</slide>
		<slide index="6" title="" titleNormalized="" src="slide7.swf" size="5378" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset6">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>7</notes>
			<notesNormalized>7</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;7&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>What this paper is about ?
Beatson (1896)

Reading list discussion
– For the first time suggests oophorectomy for treatment
 of beast cancer

– Reports two clinical cases of breast cancer with 
 very good clinical response to oophorectomy

– Illustrates the way of scientific thinking in Victorian times</text>
		</slide>
		<slide index="7" title="" titleNormalized="" src="slide8.swf" size="125267" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset7">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>8</notes>
			<notesNormalized>8</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;8&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Why I like this paper ?
Beatson (1896)

Reading list discussion</text>
		</slide>
		<slide index="8" title="" titleNormalized="" src="slide9.swf" size="60943" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset8">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>9</notes>
			<notesNormalized>9</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;9&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Why I like this paper ?
Beatson (1896)

Reading list discussion</text>
		</slide>
		<slide index="9" title="" titleNormalized="" src="slide10.swf" size="58208" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset9">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>10</notes>
			<notesNormalized>10</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;10&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Beatson’s initial idea was 
to convert breast cancer into milk 
by mean of oophorectomy

Why I like this paper ?
Beatson (1896)

Reading list discussion</text>
		</slide>
		<slide index="10" title="" titleNormalized="" src="slide11.swf" size="46978" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset10">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>11</notes>
			<notesNormalized>11</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;11&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Pre-vision of endocrine system !
Why I like this paper ?
Beatson (1896)

Reading list discussion</text>
		</slide>
		<slide index="11" title="" titleNormalized="" src="slide12.swf" size="37034" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset11">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>12</notes>
			<notesNormalized>12</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;12&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Main role of oestrogens 
in breast cancer!
Why I like this paper ?
Beatson (1896)

Reading list discussion</text>
		</slide>
		<slide index="12" title="" titleNormalized="" src="slide13.swf" size="66797" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset12">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>13</notes>
			<notesNormalized>13</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;13&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Why I like this paper ?
Beatson (1896)


Making a Unihorn ?!
Reading list discussion</text>
		</slide>
		<slide index="13" title="" titleNormalized="" src="slide14.swf" size="5203" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset13">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>14</notes>
			<notesNormalized>14</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;14&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Reading list discussion</text>
		</slide>
		<slide index="14" title="" titleNormalized="" src="slide15.swf" size="5468" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset14">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>15</notes>
			<notesNormalized>15</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;15&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Discussing reading list
Endocrine treatment in breast cancer
Breast Cancer
Oestrogen Receptor
Endocrine treatment
Short group task
Endocrine resistance in breast cancer
Impact &amp; current management
Mechanisms of endocrine resistance
Future: biomarker-guided targeted treatment and monitoring
Plan of the seminar</text>
		</slide>
		<slide index="15" title="" titleNormalized="" src="slide16.swf" size="5396" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset15">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>16</notes>
			<notesNormalized>16</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;16&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>World-wide
Most common female cancer: ~1.7M new cases each year

In the UK
~ 30% of female cancers
1 in 8 women will be affected in the life-time
~ 50,000 women are diagnosed with breast cancer ~ 12,000 women are dying of breast cancer
~ £1.5bn costs (£0.6bn health care + £0.9bn other costs)
Impact of Breast Cancer
Data for 2012-2014, from WCRF, Cancer Research UK and NCRI</text>
		</slide>
		<slide index="16" title="" titleNormalized="" src="slide17.swf" size="5544" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset16">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>17</notes>
			<notesNormalized>17</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;17&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Reproductive factors
High risk: increased exposure to oestrogens
Protective: pregnancy, breast feeding

Inheritance 
High penetrance genes (familial breast cancer, BRACA1/2, PALB2 etc.)
Low penetrance genes and multi-gene predisposition (may have no familial history)

Life style
Obesity (in post menopause only!)
Intake of saturated fat, alcohol, OC, HRT (RRs &lt;1.5) 
Breast Cancer Risk Factors</text>
		</slide>
		<slide index="17" title="" titleNormalized="" src="slide18.swf" size="5018" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset17">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>18</notes>
			<notesNormalized>18</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;18&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Breast Cancer: Relative Risks
1x</text>
		</slide>
		<slide index="18" title="" titleNormalized="" src="slide19.swf" size="5110" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset18">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>19</notes>
			<notesNormalized>19</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;19&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>1x
Breast Cancer: Relative Risks</text>
		</slide>
		<slide index="19" title="" titleNormalized="" src="slide20.swf" size="5122" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset19">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>20</notes>
			<notesNormalized>20</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;20&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Smoking for lung cancer
Breast Cancer: Relative Risks</text>
		</slide>
		<slide index="20" title="" titleNormalized="" src="slide21.swf" size="46571" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset20">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>21</notes>
			<notesNormalized>21</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;21&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Pathology and biology of tumour
Pathology
Ductal, Lobular, other rare types
- Invasive, In Situ 
Molecular mechanisms &amp; markers
- Oestrogen Receptor (ER)
- Human Epidermal Growth Factor Receptor 2 (HER2)
Breastcancer.org
Breast Cancer: Biological Diversity
Hormonal status of patient
- Pre / Post menopause</text>
		</slide>
		<slide index="21" title="" titleNormalized="" src="slide22.swf" size="88488" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset21">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>22</notes>
			<notesNormalized>22</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;22&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>A group of several distinctive cancers?
Sørlie et al, PNAS, 2003, vol. 100, no. 14, 8418–8423 
Whole genome molecular profiling
Breast Cancer: Biological Diversity</text>
		</slide>
		<slide index="22" title="" titleNormalized="" src="slide23.swf" size="10328" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset22">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>23</notes>
			<notesNormalized>23</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;23&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Surgery
Diagnosis
Dissemination
Early Breast Cancer
Local relapse
with or without axillary
lymph-node involvement
Advanced Breast Cancer
distant metastases or 
locally advanced
Typical history of disease
Breast Cancer: Clinical Diversity</text>
		</slide>
		<slide index="23" title="" titleNormalized="" src="slide24.swf" size="11088" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset23">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>24</notes>
			<notesNormalized>24</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;24&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Surgery
Diagnosis
Dissemination
Response (tumour size)
Response (size and spread)
Disease-Free Survival
3 -5+ yrs.
Overall Survival (5-10+ yrs.)
Adjuvant treatment
Neo-adjuvant treatment
(3+ months) 
Metastatic/advanced disease treatment 
Larionov &amp; Miller 2009 Future Oncology 5(9): 1415-1428
Treatment settings &amp; Response assessment
Breast Cancer: Clinical Diversity</text>
		</slide>
		<slide index="24" title="" titleNormalized="" src="slide25.swf" size="5276" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset24">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>25</notes>
			<notesNormalized>25</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;25&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Surgery
X-ray
Cytotoxic Chemotherapy 
e.g. Anthracyclines , Taxanes, Antimetabolites , DNA-cross-linking agents etc.
Endocrine Therapy
e.g. Aromatase Inhibitors or Tamoxifen for ER-positive tumours
Targeted Therapy
e.g. Herceptin for tumours with HER2 amplification
Other Treatments
e.g. pain control, immune-therapy etc.
Breast Cancer: Treatment Methods</text>
		</slide>
		<slide index="25" title="" titleNormalized="" src="slide26.swf" size="5293" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset25">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>26</notes>
			<notesNormalized>26</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;26&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Surgery
X-ray
Cytotoxic Chemotherapy 
e.g. Anthracyclines , Taxanes, Antimetabolites , DNA-cross-linking agents etc.
Endocrine Therapy
e.g. Aromatase Inhibitors or Tamoxifen for ER-positive tumours
Targeted Therapy
e.g. Herceptin for tumours with HER2 amplification
Other Treatments
e.g. pain control, immune-therapy etc.
Breast Cancer: Treatment Methods</text>
		</slide>
		<slide index="26" title="" titleNormalized="" src="slide27.swf" size="4774" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset26">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>27</notes>
			<notesNormalized>27</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;27&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Endocrine Treatment: 
Biological Rationale
Normal breast is oestrogen-dependent</text>
		</slide>
		<slide index="27" title="" titleNormalized="" src="slide28.swf" size="140794" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset27">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>28</notes>
			<notesNormalized>28</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;28&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>
Normal breast is oestrogen-dependent
Endocrine Treatment: 
Biological Rationale</text>
		</slide>
		<slide index="28" title="" titleNormalized="" src="slide29.swf" size="5511" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset28">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>29</notes>
			<notesNormalized>29</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;29&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Fact:
Oestrogens stimulate ductal tree development in puberty 
Yet to be studied:
How/if oestrogens stimulate proliferation in normal breast?

Mitotic rates are higher in luteal phase of the cycle …
Normal proliferating breast epithelium has low/no ERs …
Role of stromal signals in proliferation / response to oestrogens …
Many facts about normal breast are derived from animal models …
Normal breast is oestrogen-dependent
Endocrine Treatment: 
Biological Rationale</text>
		</slide>
		<slide index="29" title="" titleNormalized="" src="slide30.swf" size="4984" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset29">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>30</notes>
			<notesNormalized>30</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;30&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>60-70% of breast cancers express ERs

Oestrogens support growth of many ER+ve breast cancers
Facts:
Endocrine Treatment: 
Biological Rationale</text>
		</slide>
		<slide index="30" title="" titleNormalized="" src="slide31.swf" size="5474" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset30">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>31</notes>
			<notesNormalized>31</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;31&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Discussing reading list
Endocrine treatment in breast cancer
Breast Cancer
Oestrogen Receptor
Endocrine treatment
Short group task
Endocrine resistance in breast cancer
Impact &amp; current management
Mechanisms of endocrine resistance
Future: biomarker-guided targeted treatment and monitoring
Plan of the seminar</text>
		</slide>
		<slide index="31" title="" titleNormalized="" src="slide32.swf" size="12454" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset31">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>32</notes>
			<notesNormalized>32</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;32&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Oestrogen receptors and effects
ER
beta
DNA
AP1
DNA
DNA
Nucleus
Cytoplasm
Plasma membrane
associated ER
Plasma membrane
Intra-cellular
membranes
GPER
Genomic effects, mediated by changes in genes transcription
and synthesis of new proteins (hours and days)
Signalling through 
secondary messengers 
and kinase cascades
Rapid effects
(minutes)
ER
alpha
Prossnitz &amp; Barton 2011 Nature Reviews Endocrinology 7, 715; Weatherman 2006 Nature Chemical Biology 2, 175 etc</text>
		</slide>
		<slide index="32" title="" titleNormalized="" src="slide33.swf" size="13159" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset32">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>33</notes>
			<notesNormalized>33</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;33&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Oestrogen receptors and effects
ER
beta
AP1
DNA
DNA
Nucleus
Cytoplasm
Plasma membrane
associated ER
Plasma membrane
Intra-cellular
membranes
GPER
Canonical signalling through ER-alpha is 
yet most studied in BC (2015)
Signalling through 
secondary messengers 
and kinase cascades
Rapid effects
(minutes)
ER
alpha
DNA
Prossnitz &amp; Barton 2011 Nature Reviews Endocrinology 7, 715; Weatherman 2006 Nature Chemical Biology 2, 175 etc</text>
		</slide>
		<slide index="33" title="" titleNormalized="" src="slide34.swf" size="7282" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset33">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>34</notes>
			<notesNormalized>34</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;34&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Hinge
NTD (AF1)
DBD
LBD(AF2)
N
C
Domain structure of ER-alpha
C-terminal helix (H12)
DBD – DNA- binding domain
NTD – N-terminal domain
LBD – Ligand-binding domain
(binds to oestrogen)
AF1/2 – Activating features 1 / 2 (historical designation for parts 
of NTD and LBD interacting with 
Nuclear co-activators)
NTD
(AF1)
LBD
(AF2)
DBD</text>
		</slide>
		<slide index="34" title="" titleNormalized="" src="slide35.swf" size="6638" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset34">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>35</notes>
			<notesNormalized>35</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;35&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Inactive ER-alpha without ligands
Nuclear factor located in cytoplasm (?)
bound to a chaperon protein
Heat-Shock Protein 90
NTD
(AF1)
LBD
(AF2)
DBD
HSP90
NTD
(AF1)
LBD
(AF2)
DBD
HSP90</text>
		</slide>
		<slide index="35" title="" titleNormalized="" src="slide36.swf" size="11630" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset35">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>36</notes>
			<notesNormalized>36</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;36&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Activated ER-alpha (1)
NTD
(AF1)
LBD
(AF2)
DBD
HSP90
NTD
(AF1)
LBD
(AF2)
DBD
HSP90
Cytoplasm ?
Nucleus
E2
E2
Ligand binding, HSP90 release
(trans) location into nucleus</text>
		</slide>
		<slide index="36" title="" titleNormalized="" src="slide37.swf" size="7502" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset36">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>37</notes>
			<notesNormalized>37</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;37&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Activated ER-alpha (2)
NTD
(AF1)
LBD
(AF2)
DBD
NTD
(AF1)
LBD
(AF2)
DBD
E2
E2
Phosphorylation, Dimerization
P
P</text>
		</slide>
		<slide index="37" title="" titleNormalized="" src="slide38.swf" size="10500" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset37">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>38</notes>
			<notesNormalized>38</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;38&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Activated ER-alpha (3)
NTD
(AF1)
LBD
(AF2)
DBD
E2
NTD
(AF1)
LBD
(AF2)
DBD
E2
Binding to DNA on Oestrogen Responsive Elements (ERE)
5’-aGGTCA-nnn-TGACCt-3’
Palindromic sequence (may slightly vary)
Klinge, NAR, 2001, 29(14):2905
P
P
ERE</text>
		</slide>
		<slide index="38" title="" titleNormalized="" src="slide39.swf" size="10306" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset38">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>39</notes>
			<notesNormalized>39</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;39&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Activated ER-alpha (4)
NTD
(AF1)
LBD
(AF2)
DBD
E2
NTD
(AF1)
LBD
(AF2)
DBD
E2
Binding to DNA on Oestrogen Responsive Elements (ERE)
5’-aGGTCA-nnn-TGACCt-3’
Palindromic sequence (may slightly vary)
Klinge, NAR, 2001, 29(14):2905
P
P
Availability of specific ERE is tissue-specific
Local chromatin structure depends on
Pioneering factors 
FOXA1 and GATA3
Epigenetics marks
e.g. CpG methylation, histones modification
Activity of enhancers
…
ERE
GATA3
FOXA1</text>
		</slide>
		<slide index="39" title="" titleNormalized="" src="slide40.swf" size="11310" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset39">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>40</notes>
			<notesNormalized>40</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;40&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Activated ER-alpha (5)
Transcription initiation complex (RNA-polymerase-II etc.)
Transcription initiation in cooperation with AF1-dependent nuclear co-activators
(tissue-specific: uterus, bones?)
AF1-dependent
Co-activators

NTD
(AF1)
LBD
(AF2)
DBD
E2
NTD
(AF1)
LBD
(AF2)
DBD
E2
P
P
GATA3
FOXA1</text>
		</slide>
		<slide index="40" title="" titleNormalized="" src="slide41.swf" size="11428" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset40">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>41</notes>
			<notesNormalized>41</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;41&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Activated ER-alpha (6)
Transcription initiation in cooperation with AF2-dependent nuclear co-activators
(tissue-specific, including breast epithelium)
Transcription initiation complex (RNA-polymerase-II etc.)
AF2-dependent
Co-activator
NTD
(AF1)
LBD
(AF2)
DBD
E2
NTD
(AF1)
LBD
(AF2)
DBD
E2
P
P
GATA3
FOXA1</text>
		</slide>
		<slide index="41" title="" titleNormalized="" src="slide42.swf" size="9822" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset41">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>42</notes>
			<notesNormalized>42</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;42&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NTD
(AF1)
LBD
(AF2)
DBD
NTD
(AF1)
LBD
(AF2)
DBD
P
P
DNA
(ERE)
LBD
E2
DBD
DNA-bound ER-alpha
3D computer modelling based on X-ray crystallography
E2
E2
D.Goodsell , PDB: Molecule of the Month, September 2003
GATA3
FOXA1</text>
		</slide>
		<slide index="42" title="" titleNormalized="" src="slide43.swf" size="10229" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset42">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>43</notes>
			<notesNormalized>43</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;43&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NTD
(AF1)
LBD
(AF2)
DBD
NTD
(AF1)
LBD
(AF2)
DBD
P
P
DNA
(ERE)
LBD
E2
DBD
DNA-bound ER-alpha
3D computer modelling based on X-ray crystallography
E2
E2
D.Goodsell , PDB: Molecule of the Month, September 2003
Artificial position
of H12
(expected w/o E2!)
GATA3
FOXA1</text>
		</slide>
		<slide index="43" title="" titleNormalized="" src="slide44.swf" size="266224" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset43">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>44</notes>
			<notesNormalized>44</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;44&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Dimerized DNA-Binding Domain attached to ERE
DNA
(ERE)
DBD
PDB: 1HCQ
Schwabe et al, Cell, 1993, 75: 567-578 
3D computer modelling based on X-ray crystallography</text>
		</slide>
		<slide index="44" title="" titleNormalized="" src="slide45.swf" size="273683" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset44">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>45</notes>
			<notesNormalized>45</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;45&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>DNA
(ERE)
DBD
PDB: 1HCQ
Schwabe et al, Cell, 1993, 75: 567-578 
Dimerized DNA-Binding Domain attached to ERE
3D computer modelling based on X-ray crystallography</text>
		</slide>
		<slide index="45" title="" titleNormalized="" src="slide46.swf" size="324507" advanceOnTime="0" framesCount="383" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset45">
			<sounds/>
			<videos>
				<video id="video0" videoClipId="ispring.resources_23d19b48.spr0_1119396593" slides="0" repeat="1" volume="0.8000000" posterFrameId="ispring.resources_23d19b48.spr2_1119396593" playFullScreen="0" hideWhenNotPlaying="0" rewindAfterPlaying="0"/>
			</videos>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands>
				<playVideo frameIndex="0" videoId="video0" startPos="0.0000000"/>
			</videoCommands>
			<animationSteps>
				<step start="0" end="382" playTime="15.9166667" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>46</notes>
			<notesNormalized>46</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;46&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>DNA
(ERE)
DBD
PDB: 1HCQ
Schwabe et al, Cell, 1993, 75: 567-578 
Dimerized DNA-Binding Domain attached to ERE
3D computer modelling based on X-ray crystallography</text>
		</slide>
		<slide index="46" title="" titleNormalized="" src="slide47.swf" size="257692" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset46">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>47</notes>
			<notesNormalized>47</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;47&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Dimerized Ligand-Binding 
Domain with E2
3D computer modelling based on X-ray crystallography
LBD
E2
PDB: 1A52
Tanenbaum et al, PNAS, 1998, 95: 5998-6003</text>
		</slide>
		<slide index="47" title="" titleNormalized="" src="slide48.swf" size="236167" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset47">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>48</notes>
			<notesNormalized>48</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;48&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>LBD
E2
PDB: 1A52
Tanenbaum et al, PNAS, 1998, 95: 5998-6003
Dimerized Ligand-Binding 
Domain with E2
3D computer modelling based on X-ray crystallography</text>
		</slide>
		<slide index="48" title="" titleNormalized="" src="slide49.swf" size="106591" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset48">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>49</notes>
			<notesNormalized>49</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;49&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>LBD bound to Oestradiol : PDB 1A52
LBD
E2
Tanenbaum et al, PNAS, 1998, 95: 5998-6003
Single Ligand-Binding 
Domain with E2
3D computer modelling based on X-ray crystallography</text>
		</slide>
		<slide index="49" title="" titleNormalized="" src="slide50.swf" size="5459" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset49">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>50</notes>
			<notesNormalized>50</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;50&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Helix 12 in ER-alpha
LBD bound to Oestradiol : PDB 1A52
H12
Tanenbaum et al, PNAS, 1998, 95: 5998-6003
3D computer modelling based on X-ray crystallography</text>
		</slide>
		<slide index="50" title="" titleNormalized="" src="slide51.swf" size="105724" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset50">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>51</notes>
			<notesNormalized>51</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;51&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>H12
Gangloff M, J Biol Chem. 2001, 276:15059-65
LBD bound to Oestradiol : PDB 1A52
LBD bound to Oestradiol : PDB 1QKU
Tanenbaum et al, PNAS, 1998, 95: 5998-6003
Artificial position of Helix 12
could be expected in ER w/o E2
True position of Helix 12 after binding with E2
H12 closes the ligand binding pocket like a lid
Helix 12 in ER-alpha
Position of Helix 12 is flexible</text>
		</slide>
		<slide index="51" title="" titleNormalized="" src="slide52.swf" size="218352" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset51">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>52</notes>
			<notesNormalized>52</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;52&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Gangloff M, J Biol Chem. 2001, 276:15059-65
LBD bound to Oestradiol : PDB 1A52
LBD bound to Oestradiol : PDB 1QKU
Tanenbaum et al, PNAS, 1998, 95: 5998-6003
Artificial position of Helix 12
could be expected in ER w/o E2
True position of Helix 12 after binding with E2
H12 closes the ligand binding pocket like a lid
Position of Helix 12 is flexible
Helix 12 in ER-alpha</text>
		</slide>
		<slide index="52" title="" titleNormalized="" src="slide53.swf" size="5679" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset52">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>53</notes>
			<notesNormalized>53</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;53&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Gangloff M, J Biol Chem. 2001, 276:15059-65
LBD bound to Oestradiol : PDB 1A52
LBD bound to Oestradiol : PDB 1QKU
Tanenbaum et al, PNAS, 1998, 95: 5998-6003
Artificial position of Helix 12
could be expected in ER w/o E2
True position of Helix 12 after binding with E2
H12 closes the ligand binding pocket like a lid
Position of Helix 12 is flexible
Helix 12 in ER-alpha</text>
		</slide>
		<slide index="53" title="" titleNormalized="" src="slide54.swf" size="6082" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset53">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>54</notes>
			<notesNormalized>54</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;54&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Gangloff M, J Biol Chem. 2001, 276:15059-65
LBD bound to Oestradiol : PDB 1A52
LBD bound to Oestradiol : PDB 1QKU
Tanenbaum et al, PNAS, 1998, 95: 5998-6003
Artificial position of Helix 12
could be expected in ER w/o E2
True position of Helix 12 after binding with E2
H12 closes the ligand binding pocket like a lid
Position of Helix 12 is flexible
Helix 12 in ER-alpha</text>
		</slide>
		<slide index="54" title="" titleNormalized="" src="slide55.swf" size="57410" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset54">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>55</notes>
			<notesNormalized>55</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;55&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Gangloff M, J Biol Chem. 2001, 276:15059-65
LBD bound to Oestradiol : PDB 1A52
LBD bound to Oestradiol : PDB 1QKU
Tanenbaum et al, PNAS, 1998, 95: 5998-6003
Artificial position of Helix 12
could be expected in ER w/o E2
True position of Helix 12 after binding with E2
H12 closes the ligand binding pocket like a lid
Position of Helix 12 is flexible
Helix 12 in ER-alpha</text>
		</slide>
		<slide index="55" title="" titleNormalized="" src="slide56.swf" size="95861" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset55">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>56</notes>
			<notesNormalized>56</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;56&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Effect of Tamoxifen on ER-alpha conformation
Tamoxifen protrudes from the ligand binding pocket and displaces H12
LBD bound to Oestradiol : PDB 1QKU
Gangloff M, J Biol Chem. 2001, 276:15059-65
Shiau et al, Cell. 1998 95:927-37
LBD bound to Tamoxifen : PDB 3ERT 
Oestradiol 
Tamoxifen</text>
		</slide>
		<slide index="56" title="" titleNormalized="" src="slide57.swf" size="184618" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset56">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>57</notes>
			<notesNormalized>57</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;57&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>LBD bound to Oestradiol : PDB 1QKU
Gangloff M, J Biol Chem. 2001, 276:15059-65
Shiau et al, Cell. 1998 95:927-37
LBD bound to Tamoxifen : PDB 3ERT 
Oestradiol 
Tamoxifen
Effect of Tamoxifen on ER-alpha conformation
Tamoxifen protrudes from the ligand binding pocket and displaces H12</text>
		</slide>
		<slide index="57" title="" titleNormalized="" src="slide58.swf" size="217737" advanceOnTime="0" framesCount="383" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset57">
			<sounds/>
			<videos>
				<video id="video1" videoClipId="ispring.resources_2a71d660.spr0_1119412421" slides="1" repeat="1" volume="0.8000000" posterFrameId="ispring.resources_2a71d660.spr2_1119412421" playFullScreen="0" hideWhenNotPlaying="0" rewindAfterPlaying="0"/>
				<video id="video2" videoClipId="ispring.resources_2a5df758.spr0_1119413281" slides="1" repeat="1" volume="0.8000000" posterFrameId="ispring.resources_2a5df758.spr2_1119413281" playFullScreen="0" hideWhenNotPlaying="0" rewindAfterPlaying="0"/>
			</videos>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands>
				<playVideo frameIndex="0" videoId="video1" startPos="0.0000000"/>
				<playVideo frameIndex="0" videoId="video2" startPos="0.0000000"/>
			</videoCommands>
			<animationSteps>
				<step start="0" end="382" playTime="15.9166667" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>58</notes>
			<notesNormalized>58</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;58&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>LBD bound to Oestradiol : PDB 1QKU
Gangloff M, J Biol Chem. 2001, 276:15059-65
Shiau et al, Cell. 1998 95:927-37
LBD bound to Tamoxifen : PDB 3ERT 
Oestradiol 
Tamoxifen
Effect of Tamoxifen on ER-alpha conformation
Tamoxifen protrudes from the ligand binding pocket and displaces H12</text>
		</slide>
		<slide index="58" title="" titleNormalized="" src="slide59.swf" size="11528" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset58">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>59</notes>
			<notesNormalized>59</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;59&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Transcription initiation complex (RNA-polymerase-II etc.)
AF2-dependent
Co-activator
NTD
(AF1)
LBD
(AF2)
DBD
NTD
(AF1)
LBD
(AF2)
DBD
P
P
E2
E2
GATA3
FOXA1
Tamoxifen action is different
in different tissues 
Terminology based on Johnston, Breast Cancer Research, 2005(7):119 
In breast ER drives expression of “type 2” genes using AF2-dependent co-activators</text>
		</slide>
		<slide index="59" title="" titleNormalized="" src="slide60.swf" size="12223" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset59">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>60</notes>
			<notesNormalized>60</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;60&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>AF2-dependent
Co-activator
Tamoxifen acts as oestrogen antagonist
NTD
(AF1)
LBD
(AF2)
DBD
NTD
(AF1)
LBD
(AF2)
DBD
TAM
P
P
TAM
Terminology based on Johnston, Breast Cancer Research, 2005(7):119 
GATA3
FOXA1
Transcription initiation complex (RNA-polymerase-II etc.)
In breast ER drives expression of “type 2” genes using AF2-dependent co-activators
Tamoxifen action is different
in different tissues</text>
		</slide>
		<slide index="60" title="" titleNormalized="" src="slide61.swf" size="11891" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset60">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>61</notes>
			<notesNormalized>61</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;61&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NTD
(AF1)
LBD
(AF2)
DBD
NTD
(AF1)
LBD
(AF2)
DBD
P
P
Transcription initiation complex (RNA-polymerase-II etc.)
TAM
TAM
AF1-dependent
Co-activators

Not a pure ani-oestrogen, but SERM 
Selective oEstrogen Receptor Modulator
GATA3
FOXA1
Terminology based on Johnston, Breast Cancer Research, 2005(7):119 
Tamoxifen acts as oestrogen agonist
In bone and uterus ER drives “type 1” genes using AF1-dependent co-activators
Tamoxifen action is different
in different tissues</text>
		</slide>
		<slide index="61" title="" titleNormalized="" src="slide62.swf" size="24438" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset61">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>62</notes>
			<notesNormalized>62</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;62&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Activating mutations in LBD
LBD bound to E2
PDB 1QKU 
Toy et al 2013 Nat Genetics 45:1439-45
Gangloff M, J Biol Chem. 2001, 276:15059-65
Y537S LBD w/o E2
wt LBD + E2
(found in breast cancers after endocrine treatment)</text>
		</slide>
		<slide index="62" title="" titleNormalized="" src="slide63.swf" size="65611" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset62">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>63</notes>
			<notesNormalized>63</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;63&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Toy et al 2013 Nat Genetics 45:1439-45
Effect on tumour 
growth
% xenograft growth
E2 removal
Start of doxycycline
Days
Y537S LBD w/o E2
Activating mutations in LBD
(found in breast cancers after endocrine treatment)</text>
		</slide>
		<slide index="63" title="" titleNormalized="" src="slide64.swf" size="5847" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset63">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>64</notes>
			<notesNormalized>64</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;64&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Discussing reading list
Endocrine treatment in breast cancer
Breast Cancer
Oestrogen Receptor

Endocrine treatment
Short group task
Endocrine resistance in breast cancer
Impact &amp; current management
Mechanisms of endocrine resistance
Future: biomarker-guided targeted treatment and monitoring
Plan of the seminar</text>
		</slide>
		<slide index="64" title="" titleNormalized="" src="slide65.swf" size="5465" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset64">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>65</notes>
			<notesNormalized>65</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;65&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Discussing reading list
Endocrine treatment in breast cancer
Breast Cancer
Oestrogen Receptor
Endocrine treatment
Short group task
Endocrine resistance in breast cancer
Impact &amp; current management
Mechanisms of endocrine resistance
Future: biomarker-guided targeted treatment and monitoring
Plan of the seminar</text>
		</slide>
		<slide index="65" title="" titleNormalized="" src="slide66.swf" size="15570" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset65">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>66</notes>
			<notesNormalized>66</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;66&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ovary
(pre-menopause)
Peripheral tissues
(post-menopause)
Breast Cancer Cell
Oestrogen Receptor
Anti-oestrogens
Tamoxifen
Faslodex
Aromatase Inhibitors
Letrozole
Anastrozole
Exemestane
Ovarian suppression
Oophorectomy
GnRH agonists (Goserelin)
Larionov &amp; Miller, Treatment strategies, 2010
Endocrine treatment in breast cancer
Summary</text>
		</slide>
		<slide index="66" title="" titleNormalized="" src="slide67.swf" size="15656" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset66">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>67</notes>
			<notesNormalized>67</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;67&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ovary
(pre-menopause)
Peripheral tissues
(post-menopause)
Breast Cancer Cell
Oestrogen Receptor
Anti-oestrogens
Tamoxifen
Faslodex
Aromatase Inhibitors
Letrozole
Anastrozole
Exemestane
Ovarian suppression
Oophorectomy
GnRH agonists (Goserelin)
Larionov &amp; Miller, Treatment strategies, 2010
Endocrine treatment in breast cancer
Summary</text>
		</slide>
		<slide index="67" title="" titleNormalized="" src="slide68.swf" size="5712" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset67">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>68</notes>
			<notesNormalized>68</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;68&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Tamoxifen efficacy in Breast cancer
&amp; much less toxicity:
DES often caused nausea, oedema, vaginal bleeding, cardiac problems
Advanced Breast Cancer
Peethambaram et al, 1999, Breast Cancer Research and Treatment 54: 117–122
Tamoxifen vs. high doses of oestrogen
years
(DES = diethylstilboestrol)
Tamoxifen shows marginally less efficacy?</text>
		</slide>
		<slide index="68" title="" titleNormalized="" src="slide69.swf" size="5847" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset68">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>69</notes>
			<notesNormalized>69</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;69&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Oestrogen Receptors UNKNOWN
&amp; much less toxicity:
DES often caused nausea, oedema, vaginal bleeding, cardiac problems
Advanced Breast Cancer
Peethambaram et al, 1999, Breast Cancer Research and Treatment 54: 117–122
Tamoxifen vs. high doses of oestrogen
years
(DES = diethylstilboestrol)
Tamoxifen shows marginally less efficacy? 
Tamoxifen efficacy in Breast cancer</text>
		</slide>
		<slide index="69" title="" titleNormalized="" src="slide70.swf" size="66595" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset69">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>70</notes>
			<notesNormalized>70</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;70&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Advanced Breast Cancer
Tamoxifen efficacy in Breast cancer</text>
		</slide>
		<slide index="70" title="" titleNormalized="" src="slide71.swf" size="5193" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset70">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>71</notes>
			<notesNormalized>71</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;71&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Endocrine treatment is NOT effective in any Oestrogen Receptor negative (ER-ve) tumours 
Oestrogen receptor is
Endocrine treatment is effective in most (~70%) 
of Oestrogen Receptor positive (ER+ve) tumours
Endocrine treatment is indicated to
Oestrogen Receptor positive tumours ONLY
the main biomarker for endocrine treatment</text>
		</slide>
		<slide index="71" title="" titleNormalized="" src="slide72.swf" size="35061" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset71">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>72</notes>
			<notesNormalized>72</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;72&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Early Breast Cancer Trialists' Collaborative Group, Lancet, 1998, 351(9114): 1451
Early Breast Cancer
Adjuvant 
(post-operative)
treatment
Oestrogen Receptor 
positive cancers
Tamoxifen is more effective than no tamoxifen
Tamoxifen efficacy in Breast cancer</text>
		</slide>
		<slide index="72" title="" titleNormalized="" src="slide73.swf" size="37177" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset72">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>73</notes>
			<notesNormalized>73</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;73&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Early Breast Cancer Trialists' Collaborative Group, Lancet, 1998, 351(9114): 1451
Early Breast Cancer
Adjuvant 
(post-operative)
treatment
Oestrogen Receptor 
positive cancers
Tamoxifen is more effective than no tamoxifen
Tamoxifen efficacy in Breast cancer</text>
		</slide>
		<slide index="73" title="" titleNormalized="" src="slide74.swf" size="44171" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset73">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>74</notes>
			<notesNormalized>74</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;74&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Rationally designed in attempt to make an anti-oestrogen superior to Tamoxifen
“tamoxifen-like”
Droloxifene
Idoxifene
etc.
“fixed ring”
Arzoxifene
Acolbifene
etc.
SERMs
Selective Oestrogen Receptor Modulators</text>
		</slide>
		<slide index="74" title="" titleNormalized="" src="slide75.swf" size="9620" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset74">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>75</notes>
			<notesNormalized>75</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;75&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Tissue
Effect of oestrogens
Tamoxifen
Toremifene
Raloxifene
Breast
Proliferation
Carcinogenesis
Antagonist
Antagonist
Antagonist
Uterus
Proliferation
Carcinogenesis
Agonist
Agonist
Not an agonist
Bones
Preserve bone density
Agonist
Agonist
Agonist
Clinical efficacy 
Based on: Johnston, Breast Cancer Research, 2005(7):119 
No superiority over Tamoxifen
Tissue-specific effects 
SERMs</text>
		</slide>
		<slide index="75" title="" titleNormalized="" src="slide76.swf" size="39065" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset75">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>76</notes>
			<notesNormalized>76</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;76&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Fulvestrant (Faslodex)
“Pure anti-oestrogen” : no estrogenic activity at all
“Oestrogen” with added bulk side chain
Faslodex with rat’s LBD (PDB 1HJ1) 
(H12 is hot shown…)
Tamoxifen with human LBD
(for comparison, PDB 3ERT)</text>
		</slide>
		<slide index="76" title="" titleNormalized="" src="slide77.swf" size="6455" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset76">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>77</notes>
			<notesNormalized>77</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;77&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Selective oEstrogen Receptor Down-regulator (SERD)
Binds to ER → Prevents ER dimerization → Triggers ER degradation
Intramuscular: 250-500mg in 5-10 ml, monthly
Advanced BC: Superiority over Tamoxifen was not evident for 250mg …
May be effective in some Tamoxifen-resistant tumours !
“Oestrogen” with added bulk side chain
Clinical features
Mechanism
Fulvestrant (Faslodex)
“Pure anti-oestrogen” : no estrogenic activity at all</text>
		</slide>
		<slide index="77" title="" titleNormalized="" src="slide78.swf" size="5538" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset77">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>78</notes>
			<notesNormalized>78</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;78&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Breast cancer treatment in all settings: early &amp; advanced 
Recently substituted by Aromatase Inhibitors in post-menopause
Rarely used for breast cancer treatment
Breast Cancer prevention in high risk groups 
Osteoporosis prevention in post-menopause
Treatment of advanced and tamoxifen-resistant breast cancer
Use of 500mg dose may be extended in near future
Current practice with anti-oestrogens
Tamoxifen
Fulvestrant (faslodex)
Toremifene
Raloxifene
Rarely used for breast cancer treatment</text>
		</slide>
		<slide index="78" title="" titleNormalized="" src="slide79.swf" size="15648" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset78">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>79</notes>
			<notesNormalized>79</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;79&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ovary
(pre-menopause)
Peripheral tissues
(post-menopause)
Breast Cancer Cell
Oestrogen Receptor
Anti-oestrogens
Tamoxifen
Faslodex
Aromatase Inhibitors
Letrozole
Anastrozole
Exemestane
Ovarian suppression
Oophorectomy
GnRH agonists (Goserelin)
Larionov &amp; Miller, Treatment strategies, 2010
Endocrine treatment in breast cancer
Summary</text>
		</slide>
		<slide index="79" title="" titleNormalized="" src="slide80.swf" size="7643" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset79">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>80</notes>
			<notesNormalized>80</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;80&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Estrogens
Breast cancer growth
Aromatase
HO
O
O
O
Androgens
Aromatase Inhibitors (AIs)
ER+ve</text>
		</slide>
		<slide index="80" title="" titleNormalized="" src="slide81.swf" size="11601" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset80">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>81</notes>
			<notesNormalized>81</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;81&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Estrogens
Breast cancer growth
Aromatase
HO
O
O
O
Androgens
ER+ve
Aromatase Inhibitors (AIs)</text>
		</slide>
		<slide index="81" title="" titleNormalized="" src="slide82.swf" size="130126" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset81">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>82</notes>
			<notesNormalized>82</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;82&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>PDB: 3S79
Ghosh et al, J.Med.Chem , 2012, 55: 8464-8476 
Membrane
Aromatase
Hem
Androgen
Aromatase
3D computer modelling based on X-ray crystallography</text>
		</slide>
		<slide index="82" title="" titleNormalized="" src="slide83.swf" size="157357" advanceOnTime="0" framesCount="383" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset82">
			<sounds/>
			<videos>
				<video id="video3" videoClipId="ispring.resources_29712c60.spr0_1119454703" slides="1" repeat="1" volume="0.8000000" posterFrameId="ispring.resources_29712c60.spr2_1119454703" playFullScreen="0" hideWhenNotPlaying="0" rewindAfterPlaying="0"/>
			</videos>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands>
				<playVideo frameIndex="0" videoId="video3" startPos="0.0000000"/>
			</videoCommands>
			<animationSteps>
				<step start="0" end="382" playTime="15.9166667" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>83</notes>
			<notesNormalized>83</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;83&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>PDB: 3S79
Ghosh et al, J.Med.Chem , 2012, 55: 8464-8476 
Membrane
Aromatase
Hem
3D computer modelling based on X-ray crystallography
Androgen
Aromatase</text>
		</slide>
		<slide index="83" title="" titleNormalized="" src="slide84.swf" size="39728" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset83">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>84</notes>
			<notesNormalized>84</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;84&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Hong et al, Steroids, 2011, 76(8): 802 - 806 
Membrane
Aromatase &amp; NADPH-reductase
3D computer modelling based on X-ray crystallography</text>
		</slide>
		<slide index="84" title="" titleNormalized="" src="slide85.swf" size="8759" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset84">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>85</notes>
			<notesNormalized>85</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;85&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Aromatisation within the body
Pre-menopause
Post-menopause
Blood
Blood
Blood
Ovary and adrenal gland
Peripheral tissues
Adipose, Skin, Muscle (?) … , Tumour itself
Blood
Blood
Androgens
Oestrogens
Aromatase
Cholesterol 
3-4 steps
Ovary
Androgens
Cholesterol 
3-4 steps
Oestrogens
Androgens
Aromatase
In post menopause oestrogens are made in peripheral tissues
Simpson 2003 Journal of Steroid Biochemistry &amp; Molecular Biology 86: 225</text>
		</slide>
		<slide index="85" title="" titleNormalized="" src="slide86.swf" size="9098" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset85">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>86</notes>
			<notesNormalized>86</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;86&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Pre-menopause
Post-menopause
Blood
Blood
Blood
Ovary and adrenal gland
Peripheral tissues
Adipose, Skin, Muscle (?) … , Tumour itself
Blood
Blood
Androgens
Oestrogens
Aromatase
Cholesterol 
3-4 steps
Ovary
Androgens
Cholesterol 
3-4 steps
Oestrogens
Androgens
Aromatase
AI
Aromatase inhibitors are 
NOT effective in ovary !
Simpson 2003 Journal of Steroid Biochemistry &amp; Molecular Biology 86: 225</text>
		</slide>
		<slide index="86" title="" titleNormalized="" src="slide87.swf" size="7889" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset86">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>87</notes>
			<notesNormalized>87</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;87&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>3 generations of aromatase inhibitors
Generation
Steroidal
Type I
Non-steroidal
Type II
First - 1970th
Testolactone
Aminoglutethimide
Second - 1980th
Formestane
Fadrozole
Third - 1990th
Exemestane
Anastrozole
Letrozole</text>
		</slide>
		<slide index="87" title="" titleNormalized="" src="slide88.swf" size="13487" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset87">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>88</notes>
			<notesNormalized>88</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;88&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ais of the 3rd generation
Letrozole
(Femara, Novartis)
Anastrozole
(Arimidex, AstraZeneca ) 
Exemestane
(Aromasin, Pfizer )
Non
Steroidal
(Type II)
Steroidal
(Type I)
Strong &amp; Specific, all bind to catalytic cavity</text>
		</slide>
		<slide index="88" title="" titleNormalized="" src="slide89.swf" size="44212" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset88">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>89</notes>
			<notesNormalized>89</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;89&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Pharmacophore model of 
non-steroidal AIs
Letrozole
Anastrozole
Neves et al, J.Med.Chem, 2009, 52: 143 - 150</text>
		</slide>
		<slide index="89" title="" titleNormalized="" src="slide90.swf" size="9084" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset89">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>90</notes>
			<notesNormalized>90</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;90&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Inhibitor
Inhibition %
Residual %
Aminoglutethimide
90.6
9.4
Formestane (i.m.)
91.9
8.1
Anastrozole (1 mg)
96.7
3.3
Exemestane
97.9
2.1
Letrozole
98.9
1.1
Lonning et al 
Breast 1996:5:202–8, 
Clin Cancer Res 1998:4:2089–93
Effect of AIs on aromatase activity
Total peripheral aromatisation in the body</text>
		</slide>
		<slide index="90" title="" titleNormalized="" src="slide91.swf" size="9300" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset90">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>91</notes>
			<notesNormalized>91</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;91&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Breast Cancer Homogenates
µM
10
1
0.1
nM
Concentration
100
10
1
100
10
1
100
10
1
100
10
1
0
25
50
75
100
Aromatase activity (% of control)
AMG
Anastrozole
Letrozole
Exemestane
Formestane
Type II agents
Type I agents
Effect of AIs on aromatase activity</text>
		</slide>
		<slide index="91" title="" titleNormalized="" src="slide92.swf" size="13946" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset91">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>92</notes>
			<notesNormalized>92</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;92&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Letrozole
2.5mg daily 10mg daily
Anastrozole
1mg daily 10mg daily
Exemestane
 25mg daily	
Pre Post Pre Post Pre Post Pre Post Pre Post
E1 (dpm/ml)
0
60
30
Miller WR et al. J Steroid Biochem Mol Biol 2001;79:93.
Effect of AIs on total peripheral aromatization
Research setting: 59 carefully selected postmenopausal patients</text>
		</slide>
		<slide index="92" title="" titleNormalized="" src="slide93.swf" size="6161" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset92">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>93</notes>
			<notesNormalized>93</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;93&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Clinical setting: 649 postmenopausal patients, multi-centre study adjuvant Anastrozole
Ingle et al. 2015 Steroids, 99:32
Effect of AIs on blood oestrogens
Possible causes of discrepancy with 
the research data in previous slide:
Peripheral aromatization is irrelevant to ovarian estrogens (&gt;5-30pg/ml) : slip-ups in ascertaining of post-menopausal status in real clinical setting as opposed to careful selection in small pre-clinical studies?
Diversity in biology of un-selected population non detectable in small pre-clinical studies
Issues with adherence in real clinical setting?
See the 2nd part of this seminar about endocrine resistance …</text>
		</slide>
		<slide index="93" title="" titleNormalized="" src="slide94.swf" size="8219" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset93">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>94</notes>
			<notesNormalized>94</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;94&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>6
Blood sampling
Determination of aromatization
Randomization
Cross-over
Letrozole
Anastrozole
Anastrozole
12
0
Letrozole
n = 6
n = 6
Weeks
Geisler et al. J Clin Oncol. 2002;20:751
Comparison of Aromatase Inhibitors
Double-blind, randomised, cross-over comparison</text>
		</slide>
		<slide index="94" title="" titleNormalized="" src="slide95.swf" size="9369" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset94">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>95</notes>
			<notesNormalized>95</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;95&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Anastrozole vs. Letrozole, p = 0.003
92
94
96
98
100
Anastrozole
Letrozole
Cross-over 1
92
94
96
98
100
Anastrozole
Letrozole
Cross-over 2
Inhibition (%)
Geisler et al. J Clin Oncol. 2002;20:751
Comparison of Aromatase Inhibitors
Double-blind, randomised, cross-over comparison</text>
		</slide>
		<slide index="95" title="" titleNormalized="" src="slide96.swf" size="30782" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset95">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>96</notes>
			<notesNormalized>96</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;96&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Residual oestrogens levels in an adjuvant study
K.Elliott et al. Br J Surg. 2014 101:939–948
Letrozole or Anastrozole
Exemestane
Comparison of Aromatase Inhibitors</text>
		</slide>
		<slide index="96" title="" titleNormalized="" src="slide97.swf" size="34843" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset96">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>97</notes>
			<notesNormalized>97</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;97&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Reduction of proliferation in a neo-adjuvant study
Ellis et al, J Clin Oncol. 2011 29(17):2342-9
ACOSOG Z1031 study
P&lt;0.05
Clinical response rate
%
Reduction in proliferation
Ki67, %
Data from Table 1
Panel from Figure 2
63%
75%
69%
-78%
-81%
-87%
Comparison of Aromatase Inhibitors</text>
		</slide>
		<slide index="97" title="" titleNormalized="" src="slide98.swf" size="10628" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset97">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>98</notes>
			<notesNormalized>98</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;98&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Neo-adjuvant treatment 
as a research tool
Neo-adjuvant treatment (3+ months) 
Indicated to patients with large non-disseminated tumours 
to facilitate surgery or to reduce volume of surgery
Allows sequential biopsies of the same human tumour
before and after treatment
Surgery
Diagnosis
Dissemination
Neo-Adjuvant
Adjuvant
Advanced / Metastatic</text>
		</slide>
		<slide index="98" title="" titleNormalized="" src="slide99.swf" size="88982" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset98">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>99</notes>
			<notesNormalized>99</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;99&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Adding Fulvestrant to AIs
Animal model vs human trial …
Xenograft model (MCF-7 transfected with aromatase)
Clinical trial (advanced setting)
Jelovac et al, 2005, Cancer Res, 65(12):5439-44
Mehta et al ,2012, NEJM, 367(5):435-44
control
fulvestrant
letrozole
Letrozole +
fulvestrant
p=0.049
median survival
41 → 48 months
anastrozole
fulvestrant
anastrozole + 
Tumour volume (%)
Time (weeks)
Time (months)
Survival
Animal models can not capture complexity of human disease</text>
		</slide>
		<slide index="99" title="" titleNormalized="" src="slide100.swf" size="89875" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset99">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>100</notes>
			<notesNormalized>100</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;100&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Letrozole shrinks human tumour
 before after 3 months 
MAMMOGRAPHY
ULTRASOUND
 before after 3 months 
Neo-adjuvant treatment shows effects of AIs on human tumours</text>
		</slide>
		<slide index="100" title="" titleNormalized="" src="slide101.swf" size="88694" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset100">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>101</notes>
			<notesNormalized>101</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;101&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Pre
Post
Bright pink:
Cancer
cells
Pale pink:
Fibrous
stroma
Neo-adjuvant treatment shows effects of AIs on human tumours 
Letrozole reduces number of tumour cells</text>
		</slide>
		<slide index="101" title="" titleNormalized="" src="slide102.swf" size="126951" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset101">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>102</notes>
			<notesNormalized>102</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;102&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Brown staining shows an oestrogen-induced protein (PgR = Progesterone Receptors)
AIs inhibit oestrogen signalling in tumours
Neo-adjuvant treatment shows effects of AIs on human tumours</text>
		</slide>
		<slide index="102" title="" titleNormalized="" src="slide103.swf" size="96827" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset102">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>103</notes>
			<notesNormalized>103</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;103&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Brown staining shows proliferating cells (Ki67)
AIs stop tumour cells proliferation
Pre
10 days
Neo-adjuvant treatment shows effects of AIs on human tumours</text>
		</slide>
		<slide index="103" title="" titleNormalized="" src="slide104.swf" size="185009" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset103">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>104</notes>
			<notesNormalized>104</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;104&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Proliferation quickly goes down and stays low
in most (but not all) human tumours
Miller et al, Endo Rel Cancer 2005, Vol 12: S119-123
% proliferating cell (Ki67)
0
days
10-14
days
3 months
Neo-adjuvant treatment shows effects of AIs on human tumours</text>
		</slide>
		<slide index="104" title="" titleNormalized="" src="slide105.swf" size="33527" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset104">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>105</notes>
			<notesNormalized>105</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;105&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Peripheral tissues
(post-menopause)
Breast Cancer Cell
Oestrogen Receptor
Aromatase Inhibitors
Letrozole
Anastrozole
Exemestane
Ovarian suppression
Oophorectomy
GnRH agonists (Goserelin)
Larionov &amp; Miller, Treatment strategies, 2010
Anti-oestrogens
Tamoxifen
Faslodex
What is better?
Ovary
(pre-menopause)
Endocrine treatment in breast cancer
Summary</text>
		</slide>
		<slide index="105" title="" titleNormalized="" src="slide106.swf" size="32743" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset105">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>106</notes>
			<notesNormalized>106</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;106&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Advanced Breast Cancer
Letrozole superiority over Tamoxifen
Mouridsen et al, J Clin Oncol, 2003, 21(11):2101-9.</text>
		</slide>
		<slide index="106" title="" titleNormalized="" src="slide107.swf" size="115973" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset106">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>107</notes>
			<notesNormalized>107</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;107&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Letrozole superiority over Tamoxifen
Early Breast Cancer
BIG 1-98 study
Regan, Lancet Oncol 2011; 12: 1101–08</text>
		</slide>
		<slide index="107" title="" titleNormalized="" src="slide108.swf" size="144321" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset107">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>108</notes>
			<notesNormalized>108</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;108&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Evidence is collected by clinical trials
Example of a clinical trial: BIG 1-98 study
Regan, Lancet Oncol 2011; 12: 1101–08</text>
		</slide>
		<slide index="108" title="" titleNormalized="" src="slide109.swf" size="9326" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset108">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>109</notes>
			<notesNormalized>109</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;109&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Inhibitor
Neo-adjuvant treatment
Early Breast Cancer
Adjuvant treatment
Advanced breast cancer
Anastrozole
IMPACT
ATAC
TARGET
Exemestane
Semiglazov et al 2005
TEAM
EORTC 10951
Letrozole
P 024
BIG 1-98
P 025
Selected trials confirming superiority of AIs over TAM
Post-menopause only !
Only ER+ve patients, of course …
These are just a small fraction of trials in endocrine treatment and resistance.
There are many more completed and on-going: phase I, II, III, post-approval …
Focused on treatment efficacy, tolerability, combination, sequencing …</text>
		</slide>
		<slide index="109" title="" titleNormalized="" src="slide110.swf" size="28964" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset109">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>110</notes>
			<notesNormalized>110</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;110&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ovary
(pre-menopause)
Peripheral tissues
(post-menopause)
Breast Cancer Cell
Oestrogen Receptor
Anti-oestrogens
Tamoxifen
Faslodex
Aromatase Inhibitors
Letrozole
Anastrozole
Exemestane
Ovarian suppression
Oophorectomy
GnRH agonists (Goserelin)
Larionov &amp; Miller, Treatment strategies, 2010
Endocrine treatment in breast cancer
Summary</text>
		</slide>
		<slide index="110" title="" titleNormalized="" src="slide111.swf" size="8143" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset110">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>111</notes>
			<notesNormalized>111</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;111&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ovarian Suppression
Method
Features
Oophorectomy
Simple surgical procedure, absolute efficiency, low morbidity, non-reversible
Irradiation
Issues with reliability and complications
GnRH agonists
Non-invasive, effective, reversible
Current method of choice
Pre-menopausal ER-positive breast cancer
Cytotoxic chemotherapy may temporarily suppress ovarian function.
However, it is NOT a method of ovarian suppression because
menses resume after chemotherapy in most young patients (&lt;40yrs).
Note: 
Tamoxifen alone or Tamoxifen + Ovarian Suppression
Note: If combined with Ovarian Suppression, Tamoxifen may be changed to an Aromatase Inhibitor in future
Current practice for endocrine treatment</text>
		</slide>
		<slide index="111" title="" titleNormalized="" src="slide112.swf" size="8218" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset111">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>112</notes>
			<notesNormalized>112</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;112&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ovarian Suppression
Method
Features
Oophorectomy
Simple surgical procedure, absolute efficiency, low morbidity, non-reversible
Irradiation
Issues with reliability and complications
GnRH agonists
Non-invasive, effective, reversible
Current method of choice
Tamoxifen alone or Tamoxifen + Ovarian Suppression
Note: If combined with Ovarian Suppression, Tamoxifen may be changed to an Aromatase Inhibitor in future
Pre-menopausal ER-positive breast cancer
Current practice for endocrine treatment
Cytotoxic chemotherapy may temporarily suppress ovarian function.
However, it is NOT a method of ovarian suppression because
menses resume after chemotherapy in most young patients (&lt;40yrs).
Note:</text>
		</slide>
		<slide index="112" title="" titleNormalized="" src="slide113.swf" size="8214" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset112">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>113</notes>
			<notesNormalized>113</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;113&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ovarian Suppression
Method
Features
Oophorectomy
Simple surgical procedure, absolute efficiency, low morbidity, non-reversible
Irradiation
Issues with reliability and complications
GnRH agonists
Non-invasive, effective, reversible
Current method of choice
Cytotoxic chemotherapy may temporarily suppress ovarian function.
However, it is NOT a method of ovarian suppression because
menses resume after chemotherapy in most young patients (&lt;40yrs).
Note: 
Tamoxifen alone or Tamoxifen + Ovarian Suppression
Note: If combined with Ovarian Suppression, Tamoxifen may be changed to an Aromatase Inhibitor in future
Current practice for endocrine treatment
Pre-menopausal ER-positive breast cancer</text>
		</slide>
		<slide index="113" title="" titleNormalized="" src="slide114.swf" size="7426" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset113">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>114</notes>
			<notesNormalized>114</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;114&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Pharmacological ovarian suppression
GNRH is an oligo-peptide hypothalamic hormone
GNRH control over ovaries is mediated by pituitary tropic hormones (FSH, LH)
Glu 
Trp
Ser
His
Leu
Pro
Tyr
Gly
Arg
Gly
Synthetic GNRH agonists and antagonists are made by amino-acid substitutions/modifications
Pituitary
Hypothalamus
Pulsatile secretion of 
GNRH
Both Agonists and Antagonists inhibit ovarian function 
Either blocking signalling directly or disrupting pulsatile pattern of GNRH stimulation 
FSH, LH</text>
		</slide>
		<slide index="114" title="" titleNormalized="" src="slide115.swf" size="17052" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset114">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>115</notes>
			<notesNormalized>115</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;115&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Pharmacological ovarian suppression
GNRH is an oligo-peptide hypothalamic hormone
GnRH agonists
Goserelin, Buserelin, Leuprolide, Nafarelin, etc.
GnRH antagonists
Cetrorelix, Ganirelix, Abarelix, Degarelix
Goserelin
(Zoladex, AstraZeneca)

happened to be 
most tested and used 
in breast cancer
GNRH control over ovaries is mediated by pituitary tropic hormones (FSH, LH)
Glu 
Trp
Ser
His
Leu
Pro
Tyr
Gly
Arg
Gly
Synthetic GNRH agonists and antagonists are made by amino-acid substitutions/modifications
Both Agonists and Antagonists are used to inhibit ovarian function</text>
		</slide>
		<slide index="115" title="" titleNormalized="" src="slide116.swf" size="54358" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset115">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>116</notes>
			<notesNormalized>116</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;116&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Again: superiority of AI over Tam
2 months pre-operative treatment
 (STAGE study, Japan)
Masuda et al, Lancet Oncol 2012; 13: 345–52
Response rate (%)
(in combination with Goserelin)
Adjuvant treatment
Pagani et al. 2014 N Engl J Med. 371:107</text>
		</slide>
		<slide index="116" title="" titleNormalized="" src="slide117.swf" size="15580" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset116">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>117</notes>
			<notesNormalized>117</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;117&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ovary
(pre-menopause)
Peripheral tissues
(post-menopause)
Breast Cancer Cell
Oestrogen Receptor
Anti-oestrogens
Tamoxifen
Faslodex
Aromatase Inhibitors
Letrozole
Anastrozole
Exemestane
Ovarian suppression
Oophorectomy
GnRH agonists (Goserelin)
Larionov &amp; Miller, Treatment strategies, 2010
Endocrine treatment in breast cancer
Summary</text>
		</slide>
		<slide index="117" title="" titleNormalized="" src="slide118.swf" size="5513" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset117">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>118</notes>
			<notesNormalized>118</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;118&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Selected side effects 
of endocrine treatments
Adverse
Blood clotting, Gynaecological cancers
Protective
Bone density, Lipid profile
Adverse
Bone density (can be controlled by bisphosphonates)
Lipid &amp; cardio-vascular profile
Arthralgia (pain in joints)
Tamoxifen
Letrozole
Common for Ovarian suppression, Tam &amp; AIs
Menopausal symptoms: Hot flushes etc.</text>
		</slide>
		<slide index="118" title="" titleNormalized="" src="slide119.swf" size="5863" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset118">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>119</notes>
			<notesNormalized>119</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;119&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Discussing reading list
Endocrine treatment in breast cancer
Breast Cancer
Oestrogen Receptor
Endocrine treatment

Short group task
Endocrine resistance in breast cancer
Impact &amp; current management
Mechanisms of endocrine resistance
Future: biomarker-guided targeted treatment and monitoring
Plan of the seminar</text>
		</slide>
		<slide index="119" title="" titleNormalized="" src="slide120.swf" size="5347" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset119">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>120</notes>
			<notesNormalized>120</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;120&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>I have prepared 4 different tasks 
You will get one of them before the coffee break

During the break: think about it 
(get together with those who got the same task)

After the break 
There will be ~5 min for discussion within groups
(move tables/sits if necessary)

Then each group will have ~5 min to present the answer 
to the rest of the class

This is not for assessment! This is just for discussion 
Group tasks after coffee break</text>
		</slide>
		<slide index="120" title="" titleNormalized="" src="slide121.swf" size="5901" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset120">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>121</notes>
			<notesNormalized>121</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;121&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Example Task
A woman of 68 years old noted a lump in the left breast about a month ago; she was referred to the breast cancer clinic, where she was diagnosed with breast cancer. The tumour is 6 cm size with enlarged elastic mobile axillary lymph nodes. Chest X-ray, liver ultrasound and liver function tests (LFT’s) do not show signs of distant spread. Tumour biopsy confirmed invasive ductal carcinoma. Molecular markers show that tumour is oestrogen receptor positive, progesterone receptor positive, HER2 negative. No family history of breast cancer. Concomitant conditions include acute MI 5 years ago &amp; history of deep vein thrombosis; general condition is good for the patient’s age. 

Present case summary to the class. Compare the treatments below; suggest which of them may be suitable and which is not, why? 

1. Immediate mastectomy; after surgery: radiotherapy, adjuvant Tamoxifen for 5 years + Herceptin for 1 year
2. Neo-adjuvant Letrozole for 3 months, reassessment after 3 months to decide about the surgery type
3. Neo-adjuvant Fazlodex for 3 months followed by mastectomy &amp; radiotherapy, then 5 years of adjuvant Fazlodex
Suggest what might be missed in the assessment and treatments?</text>
		</slide>
		<slide index="121" title="" titleNormalized="" src="slide122.swf" size="6287" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset121">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>122</notes>
			<notesNormalized>122</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;122&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Case summary
Answers
Missed assessments
Large non-disseminated tumour in elderly post-menopausal patient
LN+ve, ER+ve, HER-ve 
History of DVT 
Immediate mastectomy; after surgery: radiotherapy, adjuvant Tamoxifen for 5 years + Herceptin for 1 year

Neo-adjuvant Letrozole for 3 months, reassessment after 3 months to decide about the surgery type

Neo-adjuvant Faslodex for 3 months followed by mastectomy &amp; radiotherapy, then 5 years of adjuvant Faslodex


?
Bone density assessment is needed to administer letrozole to post-menopausal patient
Bisphosphonates may be needed if low bone density is found.
Example Task Answers</text>
		</slide>
		<slide index="122" title="" titleNormalized="" src="slide123.swf" size="6409" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset122">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>123</notes>
			<notesNormalized>123</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;123&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Case summary
Answers
Missed assessments
Large non-disseminated tumour in elderly post-menopausal patient
LN+ve, ER+ve, HER-ve
History of DVT
Immediate mastectomy; after surgery: radiotherapy, adjuvant Tamoxifen for 5 years + Herceptin for 1 year

Neo-adjuvant Letrozole for 3 months, reassessment after 3 months to decide about the surgery type

Neo-adjuvant Faslodex for 3 months followed by mastectomy &amp; radiotherapy, then 5 years of adjuvant Faslodex . May become accepted in future – after relevant clinical trials for 500mg dosage ?


?
Bone density assessment is needed to administer letrozole to post-menopausal patient
Bisphosphonates may be needed if low bone density is found.
Example Task Answers</text>
		</slide>
		<slide index="123" title="" titleNormalized="" src="slide124.swf" size="5844" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset123">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>124</notes>
			<notesNormalized>124</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;124&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Task 1
A patient has been referred to the breast cancer clinic with suspicion on breast cancer detected on mammography screening. In the upper outer quadrant of the left breast there is a tumour ~1 cm in diameter. Ultrasound-guided tumour biopsy confirmed invasive ductal carcinoma. Molecular markers: Estrogen receptor positive, HER2 positive. Patient is 45 years old. The menses are regular. No signs of lymph nodes involvement. No signs of distant spread in liver (liver function tests and ultrasound) and lung (chest X-ray). No concomitant conditions. 

Present case summary to the class. Compare the treatments below; suggest which of them may be suitable and which is not, why? 

1. Immediate tumour removal by conservative surgery (lumpectomy). After surgery: adjuvant Tamoxifen for 5 years + Herceptin for 1 year. 
2. Mastectomy followed by radiotherapy and a course of adjuvant cytotoxic chemotherapy; Then Tamoxifen + Goserelin for 5 years. 
3. Neo-adjuvant Letrozole for 3 months followed by conservative surgery (sector resection). After surgery: 5 years of adjuvant Letrozole + Herceptin for 1 year. 
Suggest what might be missed in the assessment and treatments?</text>
		</slide>
		<slide index="124" title="" titleNormalized="" src="slide125.swf" size="6592" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset124">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>125</notes>
			<notesNormalized>125</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;125&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Task 1
Immediate tumour removal by conservative surgery (lumpectomy). After surgery: adjuvant Tamoxifen for 5 years + Herceptin for 1 year. 

Mastectomy followed by radiotherapy and a course of adjuvant cytotoxic chemotherapy; Then Tamoxifen + Goserelin for 5 years. 

Neo-adjuvant Letrozole for 3 months followed by conservative surgery (sector resection). After surgery: 5 years of adjuvant Letrozole + Herceptin for 1 year. 
Small non-disseminated tumour in pre-menopausal patient. 
LN-ve, ER+ve, HER2+ve. 
Progesterone receptors (PgR) have not been mentioned in the case description. Currently PgR assessment is the standard of practice for breast cancer. PgR brings additional information about the functional state of ER signalling in ER+ve tumours. 
Case summary
Answers
Missed assessments


?
Given the young age, the familial history should had been mentioned in the case description; in case of breast cancer in close relatives, BRCA1/2 tests should be done and treatment may need be modified …</text>
		</slide>
		<slide index="125" title="" titleNormalized="" src="slide126.swf" size="6630" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset125">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>126</notes>
			<notesNormalized>126</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;126&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Task 1
Immediate tumour removal by conservative surgery (lumpectomy). After surgery: adjuvant Tamoxifen for 5 years + Herceptin for 1 year. 

Mastectomy followed by radiotherapy and a course of adjuvant cytotoxic chemotherapy; Then Tamoxifen + Goserelin for 5 years. Where is Herceptin?

Neo-adjuvant Letrozole for 3 months followed by conservative surgery (sector resection). After surgery: 5 years of adjuvant Letrozole + Herceptin for 1 year. 
Small non-disseminated tumour in pre-menopausal patient. 
LN-ve, ER+ve, HER2+ve. 
Progesterone receptors (PgR) have not been mentioned in the case description. Currently PgR assessment is the standard of practice for breast cancer. PgR brings additional information about the functional state of ER signalling in ER+ve tumours. 
Case summary
Answers
Missed assessments


Given the young age, the familial history should had been mentioned in the case description; in case of breast cancer in close relatives, BRCA1/2 tests should be done and treatment may need be modified … 
</text>
		</slide>
		<slide index="126" title="" titleNormalized="" src="slide127.swf" size="5932" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset126">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>127</notes>
			<notesNormalized>127</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;127&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Task 2
A 65 years old woman noted a lump in low outer quadrant in the right breast. GP referred her to the breast cancer clinic. Mammography found three tumour focuses in the right breast of ~1cm, ~1.5 cm and ~3cm; with calcification. Right axillary lymph nodes are enlarged and fixed to surrounding tissues. Chest X-ray shows multiple deposits in lungs. No evidence of deposits in liver (liver function tests &amp; ultrasound are normal). No evidence of brain Mts (CT). Core-biopsy confirmed invasive ductal carcinoma. Molecular markers: Estrogen receptor positive, Progesterone receptor positive, HER2 negative. No familial history of breast cancer. No concomitant conditions. 

Present case summary to the class. Compare the treatments below; suggest which of them may be suitable and which is not, why? 

1. Mastectomy followed by a course of adjuvant cytotoxic chemotherapy; Then adjuvant tamoxifen for 5 years. 
2. A course of adjuvant cytotoxic chemotherapy; local radiotherapy, then letrozole until progression. 
3. Neo-adjuvant Faslodex for 3 months followed by conservative surgery. After surgery: Radiotherapy &amp; 5 years of adjuvant Letrozole + Herceptin for 1 year. 
Suggest what might be missed in the assessment and treatments?</text>
		</slide>
		<slide index="127" title="" titleNormalized="" src="slide128.swf" size="6322" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset127">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>128</notes>
			<notesNormalized>128</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;128&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Task 2
Mastectomy followed by a course of adjuvant cytotoxic chemotherapy; Then adjuvant tamoxifen for 5 years. 

A course of adjuvant cytotoxic chemotherapy; local radiotherapy, then letrozole until progression 

Neo-adjuvant Faslodex for 3 months followed by conservative surgery. After surgery: Radiotherapy &amp; 5 years of adjuvant Letrozole + Herceptin for 1 year. 
Disseminated breast cancer in post-menopausal patient
ER+ve, HER2-ve
Case summary
Answers
Missed assessments



Bone density assessment is needed to administer letrozole to post-menopausal patient
Missed scan for possible bone metastases (scintigraphy?)</text>
		</slide>
		<slide index="128" title="" titleNormalized="" src="slide129.swf" size="5845" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset128">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>129</notes>
			<notesNormalized>129</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;129&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Task 3
5 years ago the patient was diagnosed with operable, LN+ve, ER+ve breast cancer. The tumour was removed by mastectomy. After surgery the patient received a course of cytotoxic chemotherapy, radiotherapy and adjuvant tamoxifen. Tamoxifen still continues. Recently the patient noted a lump in the scar. Ultrasound shows a node of ~1cm. Cancer cells found in fine-needle-biopsy. No signs of nodal involvement or distant dissemination (clean chest X-ray, CT, scintigraphy, normal liver function tests). Patient is 58 years old, menses stopped shortly after the cytotoxic chemotherapy 5 years ago. No concomitant conditions. 

Present case summary to the class. Compare the treatments below; suggest which of them may be suitable and which is not, why? 

1. Switch Tamoxifen to Toremifene, repeat a course of cytotoxic chemotherapy and local radiotherapy, keep on Toremifene for 5 years (or until progression). 
2. Switch Tamoxifen to Letrozole + relapse excision + a course of cytotoxic chemotherapy + radiotherapy 
3. Relapse excision followed by a course of cytotoxic chemotherapy and radiotherapy. Then Faslodex for 5 years. 
Suggest what might be missed in the assessment and treatments?</text>
		</slide>
		<slide index="129" title="" titleNormalized="" src="slide130.swf" size="6223" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset129">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>130</notes>
			<notesNormalized>130</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;130&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Task 3
Switch Tamoxifen to Toremifene, repeat a course of cytotoxic chemotherapy and local radiotherapy, keep on Toremifene for 5 years (or until progression). Where is relapse excision?

Switch Tamoxifen to Letrozole + relapse excision + a course of cytotoxic chemotherapy + radiotherapy. 

Relapse excision followed by a course of cytotoxic chemotherapy and radiotherapy. Then Faslodex for 5 years. 
Local relapse of non-disseminated breast cancer in post-menopausal patient. 
Tamoxifen-resistant, LN-ve, ER+ve 
Missed HER2 assessment; In case of HER2-positivity: Herceptin might be added to overcome the endocrine resistance. 
Bone density assessment is needed to administer letrozole to post-menopausal patient.
Case summary
Answers
Missed assessments


</text>
		</slide>
		<slide index="130" title="" titleNormalized="" src="slide131.swf" size="16018" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset130">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>131</notes>
			<notesNormalized>131</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;131&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Ovary
(pre-menopause)
Peripheral tissues
(post-menopause)
Breast Cancer Cell
Oestrogen Receptor
Anti-oestrogens
Tamoxifen
Faslodex
Aromatase Inhibitors
Letrozole
Anastrozole
Exemestane
Ovarian suppression
Oophorectomy
GnRH agonists (Goserelin)
Larionov &amp; Miller, Treatment strategies, 2010
Endocrine treatment in breast cancer
Summary</text>
		</slide>
		<slide index="131" title="" titleNormalized="" src="slide132.swf" size="5478" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset131">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>132</notes>
			<notesNormalized>132</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;132&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Discussing reading list
Endocrine treatment in breast cancer
Breast Cancer
Oestrogen Receptor
Endocrine treatment
Short group task
Endocrine resistance in breast cancer
Impact &amp; current management
Mechanisms of endocrine resistance
Future: biomarker-guided targeted treatment and monitoring
Plan of the seminar</text>
		</slide>
		<slide index="132" title="" titleNormalized="" src="slide133.swf" size="5410" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset132">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>133</notes>
			<notesNormalized>133</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;133&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>~20% Early BC 
Progression in neo-adjuvant setting (pre-surgical)
Relapses in adjuvant setting (after surgery)

up to 90% Advanced BC
progression within 3-5 years in disseminated disease

Primary (intrinsic)
No response to neo-adjuvant (pre-surgical)
Relapse within 1-2 years after surgery
Progression within 2-6 months in advanced setting

Secondary (acquired)
After an evidence of initial response
Relapse or progression on an endocrine treatment
Endocrine resistance</text>
		</slide>
		<slide index="133" title="" titleNormalized="" src="slide134.swf" size="5558" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset133">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>134</notes>
			<notesNormalized>134</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;134&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Switch to another type of endocrine agent
Molecular profiling and monitoring

Selecting endocrine agent and addition of targeted agent(s) according to the mechanism of growth or resistance
Surgery, X-ray and Cytotoxic chemotherapy as indicated +
Current: 
Based on average evidence
Future: 
Personalised precision medicine
Endocrine component
Treatment of endocrine resistance</text>
		</slide>
		<slide index="134" title="" titleNormalized="" src="slide135.swf" size="6615" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset134">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>135</notes>
			<notesNormalized>135</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;135&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Switch to another (type of) endocrine agent
SERM
Tamoxifen
Pure anti-oestrogen
Faslodex
Aromatase Inhibitor
Letrozole, Anastrozole

Exemestane
Current approach to endocrine component at resistance</text>
		</slide>
		<slide index="135" title="" titleNormalized="" src="slide136.swf" size="5480" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset135">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>136</notes>
			<notesNormalized>136</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;136&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Discussing reading list
Endocrine treatment in breast cancer
Breast Cancer
Oestrogen Receptor
Endocrine treatment
Short group task
Endocrine resistance in breast cancer
Impact &amp; current management
Mechanisms of endocrine resistance
Future: biomarker-guided targeted treatment and monitoring
Plan of the seminar</text>
		</slide>
		<slide index="136" title="" titleNormalized="" src="slide137.swf" size="8529" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset136">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>137</notes>
			<notesNormalized>137</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;137&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Patient
Tumour
Study / healthcare
Drugs metabolism
Diversity of other escape mechanisms
Drugs target 
variants
Treatment compliance
At least 20% of poor compliance (or even worse…)
Monitoring drug in blood 
Reduction / control of adverse effects
CYP2D6 variants for Tamoxifen ?
CYP2A6 variants for Letrozole ?
Genotyping of metabolising enzymes
Somatic mutations in ER 
Germ-line mutations in Aromatase
Genotyping of ER and Aromatase genes
Response assessment
ER assessment
Ineffective block of ER signalling
Biomarkers for ER signalling in tumour
Diversity in procedures for ER assessment
1%-10% cut-offs, local pathology practices
Diverse response / resistance criteria
 Different criteria between treatment settings
Discrepancy between clinical &amp; biological response
Hormonal status
Inefficient oestrogen suppression by AIs
Monitoring of oestrogen levels on treatment
Assessment of ovarian function in (early) menopause
Multiple Causes and Aspects of Endocrine Resistance</text>
		</slide>
		<slide index="137" title="" titleNormalized="" src="slide138.swf" size="29538" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset137">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>138</notes>
			<notesNormalized>138</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;138&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Patient
Tumour
Study / healthcare
Drugs metabolism
Diversity of other escape mechanisms
Drugs target 
variants
Treatment compliance
At least 20% of poor compliance (or even worse…)
Monitoring drug in blood 
Reduction / control of adverse effects
CYP2D6 variants for Tamoxifen ?
CYP2A6 variants for Letrozole ?
Genotyping of metabolising enzymes
Somatic mutations in ER 
Germ-line mutations in Aromatase
Genotyping of ER and Aromatase genes
Response assessment
ER assessment
Ineffective block of ER signalling
Biomarkers for ER signalling in tumour
Diversity in procedures for ER assessment
1%-10% cut-offs, local pathology practices
Diverse response / resistance criteria
 Different criteria between treatment settings
Discrepancy between clinical &amp; biological response
Hormonal status
Inefficient oestrogen suppression by AIs
Monitoring of oestrogen levels on treatment
Assessment of ovarian function in (early) menopause
Multiple Causes and Aspects of Endocrine Resistance



DIVERSITY


</text>
		</slide>
		<slide index="138" title="" titleNormalized="" src="slide139.swf" size="29673" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset138">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>139</notes>
			<notesNormalized>139</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;139&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Patient
Tumour
Study / healthcare
Drugs metabolism
Diversity of other escape mechanisms
Drugs target 
variants
Treatment compliance
At least 20% of poor compliance (or even worse…)
Monitoring drug in blood 
Reduction / control of adverse effects
CYP2D6 variants for Tamoxifen ?
CYP2A6 variants for Letrozole ?
Genotyping of metabolising enzymes
Somatic mutations in ER 
Germ-line mutations in Aromatase
Genotyping of ER and Aromatase genes
Response assessment
ER assessment
Ineffective block of ER signalling
Biomarkers for ER signalling in tumour
Diversity in procedures for ER assessment
1%-10% cut-offs, local pathology practices
Diverse response / resistance criteria
 Different criteria between treatment settings
Discrepancy between clinical &amp; biological response
Hormonal status
Inefficient oestrogen suppression by AIs
Monitoring of oestrogen levels on treatment
Assessment of ovarian function in (early) menopause
Multiple Causes and Aspects of Endocrine Resistance



Most of research attention so far …

Hyper-sensitivity to low oestrogens
Cross-talk of ER with other signalling pathways
Balance of proliferation and cell death
ER independent tumour growth
Preservation of stem cells
etc.


</text>
		</slide>
		<slide index="139" title="" titleNormalized="" src="slide140.swf" size="8529" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset139">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>140</notes>
			<notesNormalized>140</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;140&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Patient
Tumour
Study / healthcare
Drugs metabolism
Diversity of other escape mechanisms
Drugs target 
variants
Treatment compliance
At least 20% of poor compliance (or even worse…)
Monitoring drug in blood 
Reduction / control of adverse effects
CYP2D6 variants for Tamoxifen ?
CYP2A6 variants for Letrozole ?
Genotyping of metabolising enzymes
Somatic mutations in ER 
Germ-line mutations in Aromatase
Genotyping of ER and Aromatase genes
Response assessment
ER assessment
Ineffective block of ER signalling
Biomarkers for ER signalling in tumour
Diversity in procedures for ER assessment
1%-10% cut-offs, local pathology practices
Diverse response / resistance criteria
 Different criteria between treatment settings
Discrepancy between clinical &amp; biological response
Hormonal status
Inefficient oestrogen suppression by AIs
Monitoring of oestrogen levels on treatment
Assessment of ovarian function in (early) menopause
Multiple Causes and Aspects of Endocrine Resistance</text>
		</slide>
		<slide index="140" title="" titleNormalized="" src="slide141.swf" size="8574" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset140">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>141</notes>
			<notesNormalized>141</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;141&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Patient
Tumour
Study / healthcare
Drugs metabolism
Diversity of other escape mechanisms
Drugs target 
variants
Treatment compliance
At least 20% of poor compliance (or even worse…)
Monitoring drug in blood 
Reduction / control of adverse effects
CYP2D6 variants for Tamoxifen ?
CYP2A6 variants for Letrozole ?
Genotyping of metabolising enzymes
Somatic mutations in ER 
Germ-line mutations in Aromatase
Genotyping of ER and Aromatase genes
Response assessment
ER assessment
Ineffective block of ER signalling
Biomarkers for ER signalling in tumour
Diversity in procedures for ER assessment
1%-10% cut-offs, local pathology practices
Diverse response / resistance criteria
 Different criteria between treatment settings
Discrepancy between clinical &amp; biological response
Hormonal status
Inefficient oestrogen suppression by AIs
Monitoring of oestrogen levels on treatment
Assessment of ovarian function in (early) menopause
Multiple Causes and Aspects of Endocrine Resistance</text>
		</slide>
		<slide index="141" title="" titleNormalized="" src="slide142.swf" size="8522" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset141">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>142</notes>
			<notesNormalized>142</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;142&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Patient
Tumour
Study / healthcare
Drugs metabolism
Diversity of other escape mechanisms
Drugs target 
variants
Treatment compliance
At least 20% of poor compliance (or even worse…)
Monitoring drug in blood 
Reduction / control of adverse effects
CYP2D6 variants for Tamoxifen ?
CYP2A6 variants for Letrozole ?
Genotyping of metabolising enzymes
Somatic mutations in ER 
Germ-line mutations in Aromatase
Genotyping of ER and Aromatase genes
Response assessment
ER assessment
Ineffective block of ER signalling
Biomarkers for ER signalling in tumour
Diversity in procedures for ER assessment
1%-10% cut-offs, local pathology practices
Diverse response / resistance criteria
 Different criteria between treatment settings
Discrepancy between clinical &amp; biological response
Hormonal status
Inefficient oestrogen suppression by AIs
Monitoring of oestrogen levels on treatment
Assessment of ovarian function in (early) menopause
Multiple Causes and Aspects of Endocrine Resistance</text>
		</slide>
		<slide index="142" title="" titleNormalized="" src="slide143.swf" size="8590" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset142">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>143</notes>
			<notesNormalized>143</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;143&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Patient
Tumour
Study / healthcare
Drugs metabolism
Diversity of other escape mechanisms
Drugs target 
variants
Treatment compliance
At least 20% of poor compliance (or even worse…)
Monitoring drug in blood 
Reduction / control of adverse effects
CYP2D6 variants for Tamoxifen ?
CYP2A6 variants for Letrozole ?
Genotyping of metabolising enzymes
Somatic mutations in ER 
Germ-line mutations in Aromatase
Genotyping of ER and Aromatase genes
Response assessment
ER assessment
Ineffective block of ER signalling
Biomarkers for ER signalling in tumour
Diversity in procedures for ER assessment
1%-10% cut-offs, local pathology practices
Diverse response / resistance criteria
 Different criteria between treatment settings
Discrepancy between clinical &amp; biological response
Hormonal status
Inefficient oestrogen suppression by AIs
Monitoring of oestrogen levels on treatment
Assessment of ovarian function in (early) menopause
Multiple Causes and Aspects of Endocrine Resistance</text>
		</slide>
		<slide index="143" title="" titleNormalized="" src="slide144.swf" size="8551" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset143">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>144</notes>
			<notesNormalized>144</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;144&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Patient
Tumour
Study / healthcare
Drugs metabolism
Diversity of other escape mechanisms
Drugs target 
variants
Treatment compliance
At least 20% of poor compliance (or even worse…)
Monitoring drug in blood 
Reduction / control of adverse effects
CYP2D6 variants for Tamoxifen ?
CYP2A6 variants for Letrozole ?
Genotyping of metabolising enzymes
Somatic mutations in ER 
Germ-line mutations in Aromatase
Genotyping of ER and Aromatase genes
Response assessment
ER assessment
Ineffective block of ER signalling
Biomarkers for ER signalling in tumour
Diversity in procedures for ER assessment
1%-10% cut-offs, local pathology practices
Diverse response / resistance criteria
 Different criteria between treatment settings
Discrepancy between clinical &amp; biological response
Hormonal status
Inefficient oestrogen suppression by AIs
Monitoring of oestrogen levels on treatment
Assessment of ovarian function in (early) menopause
Multiple Causes and Aspects of Endocrine Resistance</text>
		</slide>
		<slide index="144" title="" titleNormalized="" src="slide145.swf" size="5980" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset144">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>145</notes>
			<notesNormalized>145</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;145&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Inefficient estrogen supression by AIs
Ingle et al. 2015 Steroids, 99:32
Range of anastrozole in plasma (ng/mL): 
0
132
33
23
44
Lower quartile
2nd quartile
3rd quartile
Upper quartile
Example of a primary / intrinsic resistance mechanism
649 postmenopausal patients, 4+ weeks of adjuvant Anastrozole</text>
		</slide>
		<slide index="145" title="" titleNormalized="" src="slide146.swf" size="5632" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset145">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>146</notes>
			<notesNormalized>146</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;146&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Upper levels of E2 in
post-menopause
(vary in different sources)
Inefficient estrogen supression by AIs
Example of a primary / intrinsic resistance mechanism
Ingle et al. 2015 Steroids, 99:32
649 postmenopausal patients, 4+ weeks of adjuvant Anastrozole</text>
		</slide>
		<slide index="146" title="" titleNormalized="" src="slide147.swf" size="5845" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset146">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>147</notes>
			<notesNormalized>147</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;147&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>May explain a large proportion
of intrinsic resistance to AIs …
Inefficient estrogen supression by AIs
Example of a primary / intrinsic resistance mechanism
Ingle et al. 2015 Steroids, 99:32
649 postmenopausal patients, 4+ weeks of adjuvant Anastrozole</text>
		</slide>
		<slide index="147" title="" titleNormalized="" src="slide148.swf" size="8540" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset147">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>148</notes>
			<notesNormalized>148</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;148&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Patient
Tumour
Study / healthcare
Drugs metabolism
Diversity of other escape mechanisms
Drugs target 
variants
Treatment compliance
At least 20% of poor compliance (or even worse…)
Monitoring drug in blood 
Reduction / control of adverse effects
CYP2D6 variants for Tamoxifen ?
CYP2A6 variants for Letrozole ?
Genotyping of metabolising enzymes
Somatic mutations in ER 
Germ-line mutations in Aromatase
Genotyping of ER and Aromatase genes
Response assessment
ER assessment
Ineffective block of ER signalling
Biomarkers for ER signalling in tumour
Diversity in procedures for ER assessment
1%-10% cut-offs, local pathology practices
Diverse response / resistance criteria
 Different criteria between treatment settings
Discrepancy between clinical &amp; biological response
Hormonal status
Inefficient oestrogen suppression by AIs
Monitoring of oestrogen levels on treatment
Assessment of ovarian function in (early) menopause
Multiple Causes and Aspects of Endocrine Resistance</text>
		</slide>
		<slide index="148" title="" titleNormalized="" src="slide149.swf" size="84359" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset148">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>149</notes>
			<notesNormalized>149</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;149&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Toy et al 2013 Nat Genetics 45:1439-45
Targeting mutated ER
Mutated LBD
Vehicle
AZD9496
Tamoxifen
Fulvestrant
Lawson et al 2015, provided by AstraZeneca Oncology
Xenograft volume (mm3)
Days of treatment (supplemented with E2)
AZD9496
Activating mutations in LBD are detected in 20-50% of BC with acquired endocrine resistance
Example a secondary / acquired resistance
and its targeted treatment</text>
		</slide>
		<slide index="149" title="" titleNormalized="" src="slide150.swf" size="6833" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset149">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>150</notes>
			<notesNormalized>150</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;150&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Tumour growth
Hyper-sensitivity to low oestrogens
Cross-talk of ER with other signalling pathways
ER independent tumour growth
Preservation of stem cells

Cancer cells death
Reduction in apoptosis
Balance of proliferation and cell death

etc.
Patient
Tumour
Study / healthcare
Drugs metabolism
Diversity of other escape mechanisms
Drugs target 
variants
Treatment compliance
Response assessment
ERs assessment
Hormonal status
Multiple Causes and Aspects of Endocrine Resistance</text>
		</slide>
		<slide index="150" title="" titleNormalized="" src="slide151.swf" size="122709" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset150">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>151</notes>
			<notesNormalized>151</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;151&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>CDK6
CDK4
NF-kB
AKT
CCND1
CCNE
MYC
mTOR
P21
PTEN
ERK
RAS
PELP1
PRMT1
PI3K
P27
RBB
E2F
AP1
NCOA3
mir 221
mir 222
mir 9
HER2
GATA4
FOXP3
ER
EGFR
IGF1R
Proliferation
HO
O
Estrogen
P53
BCL2
BAK
CASP
XBP1
IRF1
TNF
etc.
Apoptosis and Survival
Estrogen signalling and resistance</text>
		</slide>
		<slide index="151" title="" titleNormalized="" src="slide152.swf" size="116322" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset151">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>152</notes>
			<notesNormalized>152</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;152&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NF-kB
AKT
CCNE
MYC
mTOR
P21
PTEN
ERK
RAS
PELP1
PRMT1
PI3K
P27
AP1
NCOA3
mir 221
mir 222
mir 9
HER2
GATA4
FOXP3
ER
EGFR
IGF1R
Proliferation
HO
O
Estrogen
CDK6
CDK4
CCND1
RBB
E2F
P53
BCL2
BAK
CASP
XBP1
IRF1
TNF
etc.
Apoptosis and Survival
Estrogen signalling and resistance</text>
		</slide>
		<slide index="152" title="" titleNormalized="" src="slide153.swf" size="115584" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset152">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>153</notes>
			<notesNormalized>153</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;153&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NF-kB
AKT
CCNE
MYC
mTOR
P21
PTEN
ERK
RAS
PELP1
PRMT1
PI3K
P27
AP1
NCOA3
mir 221
mir 222
mir 9
HER2
GATA4
FOXP3
ER
EGFR
IGF1R
Proliferation
HO
O
Estrogen
CDK6
CDK4
RBB
E2F
CCND1
Amplified in 10-20% 
of breast cancers
P53
BCL2
BAK
CASP
XBP1
IRF1
TNF
etc.
Apoptosis and Survival
Estrogen signalling and resistance</text>
		</slide>
		<slide index="153" title="" titleNormalized="" src="slide154.swf" size="118323" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset153">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>154</notes>
			<notesNormalized>154</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;154&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NF-kB
AKT
CCNE
MYC
mTOR
P21
PTEN
ERK
RAS
PELP1
PRMT1
PI3K
P27
AP1
NCOA3
mir 221
mir 222
mir 9
HER2
GATA4
FOXP3
ER
EGFR
IGF1R
Proliferation
HO
O
Estrogen
RBB
E2F
CDK6
CDK4
CCND1
Amplified in 15-25% 
of breast cancers
P53
BCL2
BAK
CASP
XBP1
IRF1
TNF
etc.
Apoptosis and Survival
Estrogen signalling and resistance</text>
		</slide>
		<slide index="154" title="" titleNormalized="" src="slide155.swf" size="122552" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset154">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>155</notes>
			<notesNormalized>155</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;155&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NF-kB
AKT
CCNE
MYC
mTOR
P21
PTEN
ERK
RAS
PELP1
PRMT1
PI3K
P27
AP1
NCOA3
mir 221
mir 222
mir 9
HER2
GATA4
FOXP3
ER
EGFR
IGF1R
Proliferation
HO
O
Estrogen
CDK6
CDK4
CCND1
RBB
E2F
Truncated isoform in 
some breast cancers
P53
BCL2
BAK
CASP
XBP1
IRF1
TNF
etc.
Apoptosis and Survival
Estrogen signalling and resistance</text>
		</slide>
		<slide index="155" title="" titleNormalized="" src="slide156.swf" size="110629" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset155">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>156</notes>
			<notesNormalized>156</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;156&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NF-kB
AKT
CCNE
MYC
mTOR
P21
PTEN
ERK
RAS
PELP1
PRMT1
PI3K
P27
AP1
NCOA3
mir 221
mir 222
mir 9
HER2
GATA4
FOXP3
ER
EGFR
IGF1R
Proliferation
HO
O
Estrogen
CDK6
CDK4
CCND1
RBB
E2F
Overexpressed in
some breast cancers
P53
BCL2
BAK
CASP
XBP1
IRF1
TNF
etc.
Apoptosis and Survival
Estrogen signalling and resistance</text>
		</slide>
		<slide index="156" title="" titleNormalized="" src="slide157.swf" size="103941" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset156">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>157</notes>
			<notesNormalized>157</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;157&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NF-kB
AKT
CCNE
MYC
mTOR
P21
PTEN
ERK
RAS
PELP1
PRMT1
PI3K
P27
AP1
NCOA3
mir 221
mir 222
mir 9
HER2
GATA4
FOXP3
ER
EGFR
IGF1R
Proliferation
HO
O
Estrogen
CDK6
CDK4
CCND1
RBB
E2F
Amplified in ~10% 
of ER+ve breast cancers
often amplified in ER-ve too !
P53
BCL2
BAK
CASP
XBP1
IRF1
TNF
etc.
Apoptosis and Survival
Estrogen signalling and resistance</text>
		</slide>
		<slide index="157" title="" titleNormalized="" src="slide158.swf" size="98165" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset157">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>158</notes>
			<notesNormalized>158</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;158&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NF-kB
AKT
CCNE
MYC
mTOR
P21
PTEN
ERK
RAS
PELP1
PRMT1
PI3K
P27
AP1
NCOA3
mir 221
mir 222
mir 9
HER2
GATA4
FOXP3
ER
EGFR
IGF1R
Proliferation
HO
O
Estrogen
P
CDK6
CDK4
CCND1
RBB
E2F
Amplified in ~10% 
of ER+ve breast cancers
often amplified in ER-ve too !
P53
BCL2
BAK
CASP
XBP1
IRF1
TNF
etc.
Apoptosis and Survival
Estrogen signalling and resistance</text>
		</slide>
		<slide index="158" title="" titleNormalized="" src="slide159.swf" size="182311" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset158">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>159</notes>
			<notesNormalized>159</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;159&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NF-kB
AKT
CCNE
MYC
mTOR
P21
PTEN
ERK
RAS
PELP1
PRMT1
PI3K
P27
AP1
NCOA3
mir 221
mir 222
mir 9
HER2
P53
BCL2
BAK
CASP
XBP1
IRF1
TNF
etc.
GATA4
FOXP3
ER
EGFR
IGF1R
Proliferation
Apoptosis and Survival
HO
O
Estrogen
CDK6
CDK4
CCND1
RBB
E2F
Estrogen signalling and resistance</text>
		</slide>
		<slide index="159" title="" titleNormalized="" src="slide160.swf" size="154089" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset159">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>160</notes>
			<notesNormalized>160</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;160&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NF-kB
AKT
CCNE
MYC
mTOR
P21
PTEN
ERK
RAS
PELP1
PRMT1
PI3K
P27
AP1
NCOA3
mir 221
mir 222
mir 9
HER2
GATA4
FOXP3
ER
EGFR
IGF1R
Proliferation
HO
O
Estrogen
CCND1
RBB
E2F
CDK6
CDK4
Everolimus (afinitor) Novartis
Ibrance (palbociclib) Pfizer
Successful targeted treatments
P53
BCL2
BAK
CASP
XBP1
IRF1
TNF
etc.
Apoptosis and Survival
Herceptin (trastusimab) Genentech</text>
		</slide>
		<slide index="160" title="" titleNormalized="" src="slide161.swf" size="65446" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset160">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>161</notes>
			<notesNormalized>161</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;161&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Combining endocrine treatments with targeted agents
Turner et al. 2015 N Engl J Med. 373:209
Fulvestrant + Palbociclib (CDK4/6 inhibitor)
Advanced breast cancer</text>
		</slide>
		<slide index="161" title="" titleNormalized="" src="slide162.swf" size="47714" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset161">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>162</notes>
			<notesNormalized>162</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;162&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Letrozole + Trastusimab (HER2 inhibitor)
Advanced breast cancer
J. Huober et al. 2012 The Breast 21:27
Combining endocrine treatments with targeted agents</text>
		</slide>
		<slide index="162" title="" titleNormalized="" src="slide163.swf" size="6689" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset162">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>163</notes>
			<notesNormalized>163</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;163&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Response rate %
(ultrasound)
Oestrogen signalling &amp; proliferation
PIK3CA mutations
Assessment of 
companion biomarkers
Clinical assessment
Exploration of 
molecular mechanisms
Letrozole + Everolimus (mTOR inhibitor) 
4 months pre-operative treatment
P=0.04
Combination
Letrozole alone
Baselga, 2009, JCO, 27:2630
58%
47%
Combining endocrine treatments with targeted agents</text>
		</slide>
		<slide index="163" title="" titleNormalized="" src="slide164.swf" size="6608" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset163">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>164</notes>
			<notesNormalized>164</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;164&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Response rate %
(ultrasound)
Oestrogen signalling &amp; proliferation
PIK3CA mutations
Assessment of 
companion biomarkers
Clinical assessment
Exploration of 
molecular mechanisms
Letrozole + Everolimus (mTOR inhibitor) 
4 months pre-operative treatment
P=0.04
Combination
Letrozole alone
58%
47%
Baselga, 2009, JCO, 27:2630
Combining endocrine treatments with targeted agents</text>
		</slide>
		<slide index="164" title="" titleNormalized="" src="slide165.swf" size="5537" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset164">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>165</notes>
			<notesNormalized>165</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;165&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Discussing reading list
Endocrine treatment in breast cancer
Breast Cancer
Oestrogen Receptor
Endocrine treatment
Short group task
Endocrine resistance in breast cancer
Impact &amp; current management
Diversity of mechanisms
Future: biomarker-guided targeted treatment and monitoring
Plan of the seminar</text>
		</slide>
		<slide index="165" title="" titleNormalized="" src="slide166.swf" size="11092" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset165">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>166</notes>
			<notesNormalized>166</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;166&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Routinely measured molecular biomarkers
Routinely measured molecular biomarkers
ER
PgR
Only ER+ve tumours respond to treatment
ER-rich PgR+ve tumours respond belter
However, ER-poor and PgR-ve still may respond
HER2
Co-expression of ER and HER2 is not common
HER2+ve tumours have worse prognosis
HER2+ve tumours require addition of Herceptin
Ki67
Measures proliferation in tumour
High proliferation on treatment indicates poor response
Translational and experimental signatures
Translational and experimental signatures
SET
Symmans et al 2010 J Clin Oncol 28:4111
Sensitivity to Endocrine Therapy (details on the next slide)
Multi-gene expression signature (165 genes)
Exploratory signature related to prognosis
PEPI
Ellis et al 2008 J Natl Cancer Inst. 100:1380
Preoperative Endocrine Prognostic Index
Includes tumour size, lymph nodes, grede, ER, Ki67
Extrapolates neo-adjuvant response to adjuvant setting
Endopredict
Kronenwett et al 2012 BMC Cancer 12:456
Multi-gene expression signature (11 genes)
Estimates prognosis for adjuvant endocrine treatment
Signatures from Edinburgh Breast Unit
Miller et al 2009 J Clin Oncol 27:1382
Turnbull et al 2015 J Clin Oncol 33:2270
Multi-gene expression signatures (4 and 205 genes)
Look at pre-treatment and on 2-weeks of treatment
Predict neo-adjuvant response after 3 months 
Selected markers for endocrine treatment</text>
		</slide>
		<slide index="166" title="" titleNormalized="" src="slide167.swf" size="81323" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset166">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>167</notes>
			<notesNormalized>167</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;167&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Genomic index for sensitivity to endocrine therapy (SET)
Expression of 165 ER-related genes instead of the single ER
Relapse-free survival in tamoxifen-treated (ER+ve) tumours
Symmans, 2010, J Clin Oncol 28:4111-4119
Low activity of ER-signalling 
despite the presence of ER? 
Biomarkers development: example 1</text>
		</slide>
		<slide index="167" title="" titleNormalized="" src="slide168.swf" size="5590" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset167">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>168</notes>
			<notesNormalized>168</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;168&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Biomarkers development: example 2
Detecting early response by short time treatment
Breast-Cancer specific Survival 
&gt;90% accuracy for 
neo-adjuvant response
4-gene predictor of neo-adjuvant response to Letrozole
that includes gene expression changes observed after 2 weeks of treatment
Arran K. Turnbull et al. JCO 2015;33:2270-2278</text>
		</slide>
		<slide index="168" title="" titleNormalized="" src="slide169.swf" size="43622" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset168">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>169</notes>
			<notesNormalized>169</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;169&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Biomarkers development: example 2
Detecting early response by short time treatment
Breast-Cancer specific Survival 
&gt;90% accuracy for 
neo-adjuvant response
4-gene predictor of neo-adjuvant response to Letrozole
that includes gene expression changes observed after 2 weeks of treatment
Arran K. Turnbull et al. JCO 2015;33:2270-2278
Early detecting of resistance, but not the mechanism!</text>
		</slide>
		<slide index="169" title="" titleNormalized="" src="slide170.swf" size="150147" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset169">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>170</notes>
			<notesNormalized>170</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;170&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Detecting of resistance mechanisms in individual tumours
Simultaneous assessment of multiple pathways
at the time of relapse/progression
Larionov &amp; Miller 2015 ISBN 978-3-319-17971-1, Fig 10.4
PIK3CA
High activity
Low activity
60 endocrine resistant tumours at the time of resistance</text>
		</slide>
		<slide index="170" title="" titleNormalized="" src="slide171.swf" size="117511" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset170">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>171</notes>
			<notesNormalized>171</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;171&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Progression-free survival (PFS) in SoFEA by ESR1 mutation status 
Charlotte Fribbens et al. 2016
doi:10.1200/JCO.2016.67.3061
Mutated ESR1
detected in ctDNA
No mutations in ESR1
detected in ctDNA
“Liquid biopsy” – detecting markers in circulating tumour DNA</text>
		</slide>
		<slide index="171" title="" titleNormalized="" src="slide172.swf" size="74131" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset171">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>172</notes>
			<notesNormalized>172</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;172&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Discussing reading list
Endocrine treatment in breast cancer
Breast Cancer
Oestrogen Receptor

Endocrine treatment

Short group task
Endocrine resistance in breast cancer
Impact &amp; current management
Diversity of mechanisms
Future: biomarker-guided targeted treatment and monitoring
Plan of the seminar</text>
		</slide>
		<slide index="172" title="" titleNormalized="" src="slide173.swf" size="10178" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset172">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>173</notes>
			<notesNormalized>173</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;173&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>NTD
(AF1)
LBD
(AF2)
DBD
NTD
(AF1)
LBD
(AF2)
DBD
P
P
E2
E2
GATA3
FOXA1
Inventing something new …
J Carrol 2015, Personal communication
FOXA1
Essential element in ER signalling
Expressed in breast, prostate &amp; liver
Apparently difficult to target directly
Not yet known 3D structure
An unknown (yet) kinase
A small-molecule inhibitor
(already known)
P
Targeting FOXA1 ?</text>
		</slide>
		<slide index="173" title="" titleNormalized="" src="slide174.swf" size="6098" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset173">
			<sounds/>
			<videos/>
			<transitionEffect name="FadeSmoothly" duration="0.7000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>174</notes>
			<notesNormalized>174</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;174&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Revisiting something old …
Progestins

Old facts

Progestin is efficient in some metastatic BC
but increases breast cancer risk as HRT (&amp; OC)…

New ideas

Single preoperative injection?
Badwe 2011 J Clin Oncol 29:2845

Combine with anti-oestrogens 
to modify ER location on chromatin?
J Carrol 2015, Personal communication
Controversial: they can cause tumour growth
BUT
Oestrogens

Old facts

Oestrogen is efficient in some metastatic BC
but stimulate growth in others …

New ideas

Make breaks in AI treatment?
Jordan &amp; Ford 2011 Cancer Prevention Research 4:633

Long-term oestrogen-deprivation 
changes response to oestrogens?
Jordan 2015 Endocrine-Related Cancer 22, R1–R31
Place for oestrogen and progestin in treatment of breast cancer ?</text>
		</slide>
		<slide index="174" title="" titleNormalized="" src="slide175.swf" size="82048" advanceOnTime="0" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset174">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="0.0000000"/>
			</animationSteps>
			<notes>175</notes>
			<notesNormalized>175</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;175&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Endocrine treatment in breast cancer

Breast Cancer
Oestrogen Receptor
Endocrine treatment
Questions ?
al720@medschl.cam.ac.uk 
Endocrine resistance in breast cancer

Impact &amp; current management
Diversity of mechanisms
Future: biomarker-guided targeted treatment</text>
		</slide>
	</slides>
</presentation>
